

CANCER GENOMICS & PROTEOMICS

Published by the International Institute of Anticancer Research

ISSN (print): 1109-6535; ISSN (online): 1790-6245

Volume 17, 2020

INDEX

Editorial Board

- A. Seth** Editor-in-Chief
Laboratory of Molecular Pathology, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre and University of Toronto, Toronto, Ontario, Canada
- G.J. Delinasios** Managing Editor and Executive Publisher
International Institute of Anticancer Research, Athens, Greece
- L.A. Aaltonen** Department of Medical Genetics, University of Helsinki, Finland
R. Abagyan The Scripps Research Institute, La Jolla, CA, USA
D.-T. Bau Terry Fox Cancer Research Lab, China Medical University Hospital, Taichung, Taiwan, ROC
R. Clarke Vincent T. Lombardi Cancer Center, Georgetown University School of Medicine, Washington, DC, USA
A.M. Dubuc Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
T. Efferth Department of Pharmaceutical Biology Institute of Pharmacy and Biochemistry, University of Mainz, Germany
N.A. Ellis Department of Cellular and Molecular Medicine, University of Arizona Cancer Center, Tucson, AZ, USA
A. Facchetti Fondazione CNAO, Pavia, Italy
J.A. Fernandes-Pol Metalloproteomics, LLC, Chesterfield, MO, USA
C.V. Forst Department of Genetics and Genomic Sciences, Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
D.S. Gerhard NIH / NCI, Office of Cancer Genomics, Bethesda, MD, USA
G. Glinsky Institute of Engineering in Medicine, University of California, San Diego, CA, USA
T.R. Golub Pediatric Oncology, Dana-Farber Cancer Institute, Cambridge, MA, USA
J. Gordon Department of Neuroscience, Center for Neurovirology, Temple University School of Medicine, Philadelphia, PA, USA
C.-H. Heldin Ludwig Institute for Cancer Research, Uppsala, Sweden
J.D. Hoheisel Deutsches Krebsforschungszentrum, Genome Research and Bioinformatics, Heidelberg, Germany
T.H.M. Huang Department of Molecular Medicine/Institute of Biotechnology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA
S.C. Jhanwar Departments of Pathology and Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
W.G. Jiang Metastasis and Angiogenesis Research Group, Department of Surgery, Cardiff University School of Medicine, Cardiff, UK
J. Ju Translational Research Laboratories, State University of New York, School of Medicine, Stony Brook, NY, USA
A. Kallioniemi Laboratory of Cancer Genetics, Institute of Medical Technology, Tampere University Hospital, Finland
O.P. Kallioniemi Medical Biotechnology Group, VTT Technical Research Centre of Finland, Turku, Finland
K. Khalili College of Science and Technology, Center for Neurovirology and Cancer Biology, Temple University, Philadelphia, PA, USA
D.G. Kieback Helios Medical Center Schleswig, Schleswig, Germany
S.D. Kottaridis Department of Virology, Hellenic Anticancer Institute, Athens, Greece
Y. T. Kwon Department of Biomedical Sciences, College of Medicine, Seoul National University, Seoul, Republic of Korea
B. Léylard-Jones Avera Cancer Institute, Sioux Falls, SD, USA
P. Lichter Deutsches Krebsforschungszentrum, Heidelberg, Germany
A. Lindblom Karolinska Hospital, Department of Molecular Medicine and Surgery, Stockholm, Sweden
G. Lubec Department of Pediatrics, University of Vienna, Austria
J. Lyons-Weiler Department of Pathology, Center for Oncology Informatics, University of Pittsburgh, PA, USA
P.J. McCormick The Center for Functional Genomics, Gen*NY*Sis Center for Excellence in Cancer Genomics, University of Albany, SUNY, Rensselaer, NY, USA
F. Mitelman Department of Clinical Genetics, University Hospital, Lund, Sweden
C. Nicot Department of Microbiology, Immunology and Molecular Genetics, University of Kansas Medical Center, Kansas City, KS, USA
L. O'Driscoll School of Pharmacy and Pharmaceutical Sciences, Trinity College, Dublin, Ireland
C.D. Platsoucas College of Sciences, Old Dominion University, Norfolk, VA, USA

J. Quackenbush	Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA
J.S. Rader	Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI, USA
R.H. Reeves	Department of Physiology, Johns Hopkins University, School of Medicine, Baltimore, MD, USA
K.L. Reichelt	Institute of Pediatric Research, The National Hospital, University of Oslo, Norway
T. Ried	Center for Cancer Research, Genetics Branch, NCI, NIH, Bethesda, MD, USA
G. Rimbach	Institute for Human Nutrition and Food Science, Christian-Albrechts-University, Kiel, Germany
K.D. Rodland	Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA, USA
C. Sansom	The School of Crystallography, Birbeck College, University of London, UK
N.A. Saunders	Centre for Immunology and Cancer Research, Princess Alexandra Hospital, University of Queensland, Australia
B.W. Schäfer	Department of Oncology, University Children's Hospital, Zurich, Switzerland
J. Schneider	Universidad Rey Juan Carlos, Facultad de Ciencias de la Salud, Alcorcón (Madrid), Spain
O.J. Semmes	Department of Microbiology and Molecular Cell Biology, Eastern Virginia Medical School, Norfolk, VA, USA
G.V. Sherbet	University of Newcastle, Merz Court, Department of Electrical and Electronic Engineering, Newcastle-upon-Tyne, UK
S. Smith	City of Hope Cancer Center, Department of Cell and Tumor Biology, Duarte, CA, USA
J.C. Strefford	Cancer Science Division, Southampton General Hospital, Southampton, UK
J.M. Trent	Tgen, Phoenix, AZ, USA
G. Tsangaris	Foundation of Biomedical Research of the Academy of Athens, Central Unit of Genomics-Proteomics, Athens, Greece
U.H. Weidle	Roche Pharma Research and Early Development (pRED), Roche Diagnostics GmbH, Penzberg, Germany
A.T. Yeung	Fox Chase Cancer Center, Philadelphia, PA, USA
H. Zhang	Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT, USA

Articles in CANCER GENOMICS & PROTEOMICS are regularly indexed in the following bibliographic services: PubMed, PubMed Central, MEDLINE, CAS (Chemical Abstracts Service); Biological Abstracts; EMBASE and BIOBASE; Compendex, GEOBASE; EMBiology; FLUIDEX; Scopus (Elsevier Bibliographic Databases); BIOSIS Previews; Science Citation Index Expanded (Web of Science); Essential Science Indicators; Google Scholar; LEEDS MEDICAL INFORMATION; CSA ILLUMINA (Cambridge Scientific Abstracts, including: Oncogenes & Growth Factors, Genetics, Medical & Pharmaceutical Biotechnology, Bioengineering); All-Russian Institute of Scientific and Technical Information – VINITI Abstracts Journal; PubsHub; Sociedad Iberoamericana de Información Científica (SIIC) Data Bases.

Editorial Office: International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Road, P.O. Box 22, Kapandriti, Attiki, 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389. Web: www.iiar-anticancer.org; www.cgp.iiarjournals.org.

Editorial Office in U.S.A.: Anticancer Research USA, Inc., 111 Bay Avenue, Highlights, NJ 07732, USA.

E-mail: journals@iiar-anticancer.org. Managing Editor: editor@iiar-anticancer.org.

Web: www.iiar-anticancer.org; www.cgp.iiarjournals.org.

Manuscripts and correspondence should be addressed to: Dr. George J. Delinasios, Managing Editor, Editorial Office, Cancer Genomics & Proteomics, 1st km Kapandritiou-Kalamou Road, P.O. Box 22, Kapandriti, Attiki, 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389, e-mail: editor@iiar-anticancer.org

Manuscripts from North America may be sent to the Editor-in-Chief, Prof. A. Seth, CGP, Laboratory of Molecular Pathology, Sunnybrook Research Institute, 2075 Bayview Avenue, Room S112a, Toronto, ON, Canada M4N 3M5. Fax: +1 416 480 5737, e-mail: genomics.proteomics@utoronto.ca

Acknowledgements

The following Organisations supported many of the works published in CANCER GENOMICS & PROTEOMICS, Volume 17, 2020.

- 90th Anniversary of Chulalongkorn University,
Rachadapisek Sompote Fund, Bangkok, Thailand
Asia University, Taichung, Taiwan, R.O.C.
AstraZeneca plc, Cambridge, U.K.
Atomic-bomb Survivors Hospital, Hiroshima, Japan
- Basic Science Research Program, National Research
Foundation of Korea (NRF), Ministry of Science and
ICT (MSIT), Gwacheon, Republic of Korea
Belgian Interuniversity Attraction Poles (IAP) Program,
Belgium
Bio & Medical Technology Development Program, Basic
Science Research Program, National Research
Foundation of Korea, Gwacheon, Republic of Korea
Biobank of Chungnam National University Hospital,
Daejeon, Republic of Korea
Biotechnology and Biological Sciences Research Council,
Swindon, U.K.
Breast Cancer Hope Foundation, London, U.K.
- Cardiff University, Cardiff, U.K.
Center of Investigation on Environment Genetics and
Oncobiology (CIMAGO), Faculty of Medicine,
University of Coimbra, Coimbra, Portugal
Centre National de la Recherche Scientifique (CNRS),
Paris, France
Centre Scientifique de Monaco, Monaco
Chang Gung Memorial Hospital, Chiayi City, Taiwan, R.O.C.
Charles University Research Fund (PROGRES), Charles
University in Prague, Prague, Czech Republic
China Medical University Hospital Cancer Research Center
of Excellence, Taichung, Taiwan, R.O.C.
China Medical University Hospital, Taichung, Taiwan,
R.O.C.
China Medical University, Taichung, Taiwan, R.O.C.
Chungnam National University Hospital Research Fund,
Daejeon, Republic of Korea
Consejo Nacional de Ciencia y Tecnología (CONACyT),
Mexico City, Mexico
Conselho Nacional de Desenvolvimento Científico e
Tecnológico (CNPq), Brasília, Brazil
Coordenação de Aperfeiçoamento de Pessoal de Nível
Superior (CAPES), Brasília, Brazil
- Daiwa Securities Health Foundation, Tokyo, Japan
Department of Molecular Medicine, University of Pavia,
Pavia, Italy
- Department of Otorhinolaryngology Head and Neck
Surgery, University Hospital Mannheim, Mannheim,
Germany
Department of Pathology, Brigham and Women's Hospital,
Boston, MA, U.S.A.
Department of Pathology, Kangbuk Samsung Hospital,
Sungkyunkwan University School of Medicine, Seoul,
Republic of Korea
Dept. of Biology and Biotechnology "L. Spallanzani",
University of Pavia, Pavia, Italy
- E-Da Hospital, Kaohsiung, Taiwan, R.O.C.
Ensign Foundation, Salt Lake City, UT, U.S.A.
European Regional Development Fund (ERDF), Brussels,
Belgium
Evandro Chagas Institute, State of Pará, Brazil
- Fels Institute, Philadelphia, PA, U.S.A.
Flemish Agency for Innovation by Science and Technology,
Belgium
French Ligue Régionale Contre Le Cancer – Comités du
Puy-de-Dôme et de l'Allier, France
Fujian Provincial Health Department Young and Middle-
aged Talents Training, Fujian Province, P.R. China
Fujian Provincial Natural Science Foundation, Fujian
Province, P.R. China
- GEMLUC, Monaco
Genomic Medicine Research Core Laboratory, Chang Gung
Memorial Hospital, Chiayi City, Taiwan, R.O.C.
Grant-in-Aid for Scientific Research on Innovative Areas,
Japan
Grant-in-Aid, Takeda Science Foundation, Japan
Grants-in-Aid for Scientific Research (KAKENHI), Japan
Society for the Promotion of Science (JSPS), Tokyo,
Japan Kaohsiung Medical University
- Hammersmith Hospital, Imperial College Healthcare NHS
Trust, London, U.K.
Health and Welfare Surcharge of Tobacco Products,
Taiwan, R.O.C.
Hiroshima Red Cross Hospital, Hiroshima, Japan
- Iizuka Hospital, Iizuka, Japan
Institute for Bio-Medical Convergence, Incheon St. Mary's
Hospital, College of Medicine, The Catholic University
of Korea, Seoul, Republic of Korea

- Institute of Biomathematics, University Hospital
Mannheim, Mannheim, Germany
- Institute of Research on Cancer and Aging in Nice
(IRCAN), Nice, France
- Instituto Evandro Chagas/SVS/MSand PAPQ-PROPESP
(UFPA), State of Pará, Brazil
- Integrative Genomics and Bioinformatics Core and the
Cytogenetics Core, National Cancer Institute, National
Institutes of Health, U.S.A.
- International Joint Usage/Research Center, Japan
- Italian Ministry of Education, University and Research
(MIUR), Italy
- Jagiellonian University Medical College, Kraków, Poland
- Japan Society for the Promotion of Science Grant-in-Aid
for Science Research, Japan
- Japanese Foundation for Multidisciplinary Treatment of
Cancer, Japan
- Joint Funds for the Innovation of Science and Technology,
Fujian Province, P.R. China
- Joint Usage/Research Center (RIRBM), Hiroshima
University, Hiroshima, Japan
- Kaohsiung Medical University Hospital, Kaohsiung,
Taiwan, R.O.C.
- Kaohsiung Medical University Research Center,
Kaohsiung, Taiwan, R.O.C.
- KU Leuven Research Fund, Belgium
- Ligue Genevoise Contre le Cancer, Genève, Switzerland
- Ministry of Education, Culture, Sports, Science and
Technology of Japan, Japan
- Ministry of Health of the Czech Republic by the Czech
Health Research Council, Czech Republic
- Ministry of Science and Technology of Taiwan, Taiwan, R.O.C.
- Naito Foundation, Japan
- National Cancer Center Research and Development Fund,
Japan Agency for Medical Research and Development
(AMED), Japan
- National Center for Genome Medicine, Ministry of Science
and Technology of Taiwan, Taiwan, R.O.C.
- National Clinical Key Specialty Construction Project
(General Surgery) of China,
- National Institute of Minority Health and Health
Disparities, National Institutes of Health
- National Natural Science Foundation of China,
P.R. China
- National Sustainability Program I (NPU I), Ministry of
Education Youth and Sports of the Czech Republic,
Czech Republic
- OITA Cancer Research Foundation, Oita, Japan
Oita Red Cross Hospital, Oita, Japan
- Peking University, Beijing, P.R. China
- Perelman School of Medicine, University of Pennsylvania,
PA, U.S.A.
- Pharmaceutical Research Instrument Center, Faculty of
Pharmaceutical Sciences, Chulalongkorn University,
Bangkok, Thailand
- PON MIUR, Biomis -Ca.Re.Bios, Italy
- Priority Issue on Post-K Computer, Japan
- Project of Science and Technology Research Program in
Fujian Province, Fujian Province, P.R. China
- Radboud Oncology Funding, Nijmegen, the Netherlands
- Radiumhospitalets Legater, Oslo, Norway
- Research Foundation-Flanders, Brussels, Belgium
- Samsung Medical Center Intramural Grant, Seoul,
Republic of Korea
- Stichting Ruby and Ros, Harderwijk, the Netherlands
- Taichung Tzu Chi Hospital, Taichung, Taiwan, R.O.C.
- Takeda Science Foundation, Japan
- Taoyuan General Hospital, Ministry of Health and Welfare,
Taiwan, R.O.C.
- Thailand Research Fund, Bangkok, Thailand
- Universidad Nacional Autónoma de México (UNAM),
Mexico City, Mexico
- University Côte d'Azur, Biot, France
- University of Heidelberg, Heidelberg, Germany
- University of Pisa, Pisa, Italy
- University of Tokyo, Tokyo, Japan
- US Army Medical Research and Materiel Command,
Maryland, U.S.A.
- Wellcome Trust Grant, London, U.K.
- Yonsei University College of Medicine, Seoul,
Republic of Korea

Contents, Volume 17, 2020

Number 1, January-February

<i>Review: MicroRNAs Involved in Metastasis of Hepatocellular Carcinoma: Target Candidates, Functionality and Efficacy in Animal Models and Prognostic Relevance. U.H. WEIDLE, D. SCHMID, F. BIRZELE, U. BRINKMANN (Penzberg, Germany; Basel, Switzerland)</i>	1
TRAF6-Mediated Inflammatory Cytokines Secretion in LPS-induced Colorectal Cancer Cells Is Regulated by miR-140. G. ZHU, C. LIN, Z. CHENG, Q. WANG, R.M. HOFFMAN, S.R. SINGH, Y. HUANG, W. ZHENG, S. YANG, J. YE (<i>Fuzhou, PR China; San Diego, CA; Frederick, MD, USA</i>)	23
PPAR γ Agonist Pioglitazone in Combination With Cisplatin Arrests a Chemotherapy-resistant Osteosarcoma PDOX Model. T. HIGUCHI, J. YAMAMOTO, N. SUGISAWA, Y. TASHIRO, H. NISHINO, N. YAMAMOTO, K. HAYASHI, H. KIMURA, S. MIWA, K. IGARASHI, M. BOUVET, S.R. SINGH, H. TSUCHIYA, R.M. HOFFMAN (<i>San Diego, CA; Frederick, MD, USA; Kanazawa, Japan</i>)	35
Chromosome Translocation t(14;21)(q11;q22) Activates Both <i>OLIG1</i> and <i>OLIG2</i> in Pediatric T-cell Lymphoblastic Malignancies and May Signify Adverse Prognosis. I. PANAGOPOULOS, L. GORUNOVA, I.M.R. JOHANNSDOTTIR, K. ANDERSEN, A. HOLTH, K. BEISKE, S. HEIM (<i>Oslo, Norway</i>)	41
Increased Expression of Gremlin1 Promotes Proliferation and Epithelial Mesenchymal Transition in Gastric Cancer Cells and Correlates With Poor Prognosis of Patients With Gastric Cancer. Z. SUN, S. CAI, C. LIU, Y. CUI, J. JI, W.G. JIANG, L. YE (<i>Cardiff, UK; Beijing, PR China</i>)	49
Therapeutic Efficacy Evaluation of Pegylated Liposome Encapsulated With Vinorelbine Plus ¹¹¹ In Repeated Treatments in Human Colorectal Carcinoma With Multimodalities of Molecular Imaging. Y.-C. CHIEN, Y.-H. CHOU, W.-H. WANG, J.C.-H. CHEN, W.-S. CHANG, C.-W. TSAI, D.-T. BAU, J.-J. HWANG (<i>Kaohsiung; Taichung; Changhua; New Taipei City, Taiwan, ROC</i>)	61
BRD4-Regulated Molecular Targets in Mantle Cell Lymphoma: Insights into Targeted Therapeutic Approach. T. TSUKAMOTO, S. NAKAHATA, R. SATO, A. KANAI, M. NAKANO, Y. CHINEN, S. MAEGAWA-MATSUI, Y. MATSUMURA-KIMOTO, T. TAKIMOTO-SHIMOMURA, Y. MIZUNO, S. KUWAHARA-OTA, Y. KAWAJI, M. TANIWAKI, T. INABA, K. TASHIRO, K. MORISHITA, J. KURODA (<i>Kyoto; Miyazaki; Hiroshima, Japan</i>)	77
Transcriptomic Analysis in Liquid Biopsy Identifies Circulating PCTAIRE-1 mRNA as a Biomarker in NSCLC. J.W.-C. CHANG, C.-L. SHIH, C.-L. WANG, J.-D. LUO, C.-W. WANG, J.-J. HSIEH, C.-J. YU, C.-C. CHIOU (<i>Taoyuan, Taiwan, ROC; New York, NY, USA</i>)	91

Number 2, March-April

Duplex DNA from Sites of Helicase-Polymerase Uncoupling Links Non-B DNA Structure Formation to Replicative Stress. C. AMPARO, J. CLARK, V. BEDELL, J.L. MURATA-COLLINS, M. MARTELLA, F. PICHIORRI, E.F. WARNER, M.A.S. ABDELHAMID, Z.A.E. WALLER, S.S. SMITH (<i>Duarte, CA, USA; Norwich, UK</i>)	101
The Search for Molecular Markers in a Gene-Orphan Case Study of a Pediatric Spinal Cord Pilocytic Astrocytoma. C. MARTINELLI, F. GABRIELE, F. MANAI, R. CICCONE, F. NOVARA, E. SAUTA, R. BELLAZZI, M. PATANE, I. MORONI, R. PATERRA, S. COMINCINI (<i>Pavia; Milan, Italy</i>)	117
Pazopanib Inhibits Tumor Growth, Lymph-node Metastasis and Lymphangiogenesis of an Orthotopic Mouse of Colorectal Cancer. G. ZHU, M. ZHAO, Q. HAN, Y. TAN, Y. SUN, M. BOUVET, S.R. SINGH, J. YE, R.M. HOFFMAN (<i>San Diego, CA; Frederick, MD, USA; Fuzhou, PR China</i>)	131

KIF15 Expression in Tumor-associated Monocytes Is a Prognostic Biomarker in Hepatocellular Carcinoma. A. KITAGAWA, T. MASUDA, J. TAKAHASHI, T. TOBO, M. NODA, Y. KURODA, Q. HU, Y. KOUYAMA, Y. KOBAYASHI, S. KURAMITSU, K. SATO, A. FUJII, Y. YOSHIKAWA, H. WAKIYAMA, D. SHIMIZU, Y. TSURUDA, H. EGUCHI, Y. DOKI, M. MORI, K. MIMORI (<i>Oita; Osaka; Fukuoka, Japan</i>)	141
Clonal Relationship Between Lichen Sclerosus, Differentiated Vulvar Intra-epithelial Neoplasia and Non HPV-related Vulvar Squamous Cell Carcinoma. A.-F.W. POUWER, L.C.G. VAN DEN EINDEN, M. VAN DER LINDEN, J.Y. HEHIR-KWA, J. YU, K.M. HENDRIKS, E.J. KAMPING, A. EIJKELBOOM, L.F.A.G. MASSUGER, J. BULTEN, A.A.G. VAN TILBORG, J.A. DE HULLU, R.P. KUIPER (<i>Nijmegen; Utrecht, the Netherlands</i>)	151
<i>FOS-ANKH</i> and <i>FOS-RUNX2</i> Fusion Genes in Osteblastoma. I. PANAGOPOULOS, L. GORUNOVA, I. LOBMAIER, K. ANDERSEN, I. KOSTOLOMOV, M. LUND-IVERSEN, B. BJERKEHAGEN, S. HEIM (<i>Oslo, Norway</i>)	161
Stratification Using hTERT and Stem Cell Markers Confers a Good Prognosis in Invasive Breast Cancer. U. WAZIR, S. TAYEH, M.A.W. ORAKZAI, T.A. MARTIN, W.G. JIANG, K. MOKBEL (<i>London; Cardiff, UK; Peshawar, Pakistan</i>)	169
Significant Association Between the MiR146a Genotypes and Susceptibility to Childhood Acute Lymphoblastic Leukemia in Taiwan. J.-S. PEI, W.-S. CHANG, P.-C. HSU, C.-C. CHEN, Y.-T. CHIN, T.-L. HUANG, Y.-N. HSU, C.-C. KUO, Y.-C. WANG, C.-W. TSAI, C.-L. GONG, D.-T. BAU (<i>Taoyuan; Taichung, Taiwan, ROC</i>)	175
Tumor Mutational Patterns and Infiltrating Lymphocyte Density in Young and Elderly Patients With Breast Cancer. A. NIKOLAIDI, V. KOTOULA, G.-A. KOLIOU, E. GIANNOULATOU, K. PAPADOPOULOU, F. ZAGOURI, G. PENTHEROUDAKIS, H. GOGAS, M. BOBOS, K. CHATZOPOULOS, G. OIKONOMOPOULOS, D. PECTASIDES, E. SALOUSTROS, N. ARNOGIANNAKI, I. NICOLAOU, P. PAPAKOSTAS, I. BOMPOLAKI, G. ARAVANTINOS, I. ATHANASIADIS, G. FOUNTZILAS (<i>Athens; Thessaloniki; Ioannina; Piraeus; Larissa; Chania, Greece; Darlinghurst; Kensington, NSW, Australia; Limassol, Cyprus</i>)	181
Identification of Novel Prognosis and Prediction Markers in Advanced Prostate Cancer Tissues Based on Quantitative Proteomics. O.K. KWON, Y.-S. HA, A.-Y. NA, S.Y. CHUN, T.G. KWON, J.N. LEE, S. LEE (<i>Daegu, Republic of Korea</i>)	195
Genetic Association Analysis of Cell Cycle Regulators Reveals <i>YWHAZ</i> Has Prognostic Significance in Prostate Cancer. C.-C. YU, L.-C. CHEN, W.-H. LIN, V.C. LIN, C.-Y. HUANG, T.-L. LU, C.-H. LEE, S.-P. HUANG, B.-Y. BAO (<i>Kaohsiung; Taipei; Pingtung; New Taipei City; Taichung, Taiwan, ROC</i>)	209

Number 3, May-June

A Novel Anionic-phosphate-platinum Complex Effectively Targets a Cisplatin-resistant Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model. K. IGARASHI, K. KAWAGUCHI, N. YAMAMOTO, K. HAYASHI, H. KIMURA, S. MIWA, T. HIGUCHI, Y. TANIGUCHI, H. YONEZAWA, Y. ARAKI, S. MORINAGA, S. MISRA, S.D. NELSON, S.M. DRY, Y. LI, A. ODANI, S.R. SINGH, H. TSUCHIYA, R.M. HOFFMAN (<i>San Diego; Los Angeles, CA; Frederick, MD, USA; Kanazawa, Japan</i>)	217
Putative Biomarkers for Malignant Pleural Mesothelioma Suggested by Proteomic Analysis of Cell Secretome. S. LACERENZA, F. CIREGIA, L. GIUSTI, A. BONOTTI, V. GRECO, G. GIANNACCINI, V. D'ANTONGIOVANNI, P. FALLAHI, L. PIERONI, A. CRISTAUDO, A. LUCACCHINI, M.R. MAZZONI, R. FODDIS (<i>Pisa; Camerino; Rome, Italy; Liège, Belgium</i>)	225
<i>NDRG1-PLAG1</i> and <i>TRPS1-PLAG1</i> Fusion Genes in Chondroid Syringoma. I. PANAGOPOULOS, L. GORUNOVA, K. ANDERSEN, M. LUND-IVERSEN, I. LOBMAIER, F. MICCI, S. HEIM (<i>Oslo, Norway</i>)	237

Tumor microRNAs Identified by Small RNA Sequencing as Potential Response Predictors in Locally Advanced Rectal Cancer Patients Treated With Neoadjuvant Chemoradiotherapy. T. MACHACKOVA, K. TRACHTOVA, V. PROCHAZKA, T. GROlich, M. FARKASOVA, L. FIALA, R. SEFR, I. KISS, M. SKROVINA, M. DOSOUDIL, I. BERINDAN-NEAGOE, M. SVOBODA, O. SLABY, Z. KALA (<i>Brno; Novy Jicin; Olomouc, Czech Republic; Cluj-Napoca, Romania</i>).....	249
Proteomics-based Predictive Model for the Early Detection of Metastasis and Recurrence in Head and Neck Cancer. I.P. RIBEIRO, L. ESTEVES, S.I. ANJO, F. MARQUES, L. BARROSO, B. MANADAS, I. MARQUES CARREIRA, J. BARBOSA MELO (<i>Coimbra, Portugal</i>).....	259
Co-occurrent Alterations of Alzheimer’s Genes and Prostate Cancer Genes in Prostate Cancer. S. LEHRER, P.H. RHEINSTEIN (<i>New York, NY; Severna Park, MD, USA</i>).....	271
Prognostic Biomarkers in Early-stage Gastric Adenocarcinoma Treated With Adjuvant Chemoradiotherapy. E. PECTASIDES, I. CHATZIDAKIS, V. KOTOULA, G.-A. KOLIOU, K. PAPADOPOULOU, E. GIANNOULATOU, V.G. GIANNOUZAKOS, M. BOBOS, C. PAPAVASILEIOU, S. CHRISAFI, A. FLOROU, D. PECTASIDES, G. FOUNTZILAS (<i>Boston, MA, USA; Athens; Thessaloniki, Greece; Darlinghurst; Kensington, NSW, Australia; Limassol, Cyprus</i>).....	277
The Clinical Relevance of Frequent Germline Genetic Variants Detected by Targeted Sequencing in Patients With Rectal Adenocarcinoma (READ). K.C.-Y. HUANG, S.-F. CHIANG, T.-W. KE, W.T.-L. CHEN, T.-W. CHEN, K.-S.C. CHAO (<i>Taichung, Taiwan, ROC</i>).....	291
The Role of Circulating Adiponectin and SNP276G>T at <i>ADIPOQ</i> Gene in <i>BRCA</i> -mutant Women. A. DANIELE, A.V. PARADISO, R. DIVELLA, M. DIGENNARO, M. PATRUNO, S. TOMMASI, B. PILATO, A. TUFARO, M. BARONE, C. MINOIA, D. COLANGELO, E. SAVINO, P. CASAMASSIMA, E. BRUNO, A. OLIVERIO, P. PASANISI (<i>Bari; Milan, Italy</i>).....	301
Prognostic Significance of Transient Receptor Potential Vanilloid Type 1 (TRPV1) and Phosphatase and Tension Homolog (PTEN) in Epithelial Ovarian Cancer. G.H. HAN, D.B. CHAY, S. NAM, H. CHO, J.-Y. CHUNG, J.-H. KIM (<i>Seoul, Republic of Korea; Bethesda, MD, USA</i>).....	309

Number 4, July-August

Identification of MicroRNAs With <i>In Vivo</i> Efficacy in Multiple Myeloma-related Xenograft Models. U.H. WEIDLE, A. NOFORA (<i>Penzberg, Germany</i>).....	321
Anticancer Effects of Nutraceuticals in the Mediterranean Diet: An Epigenetic Diet Model. R. DIVELLA, A. DANIELE, E. SAVINO, A. PARADISO (<i>Bari, Italy</i>).....	335
Eribulin Regresses a Doxorubicin-resistant Dedifferentiated Liposarcoma in a Patient-derived Orthotopic Xenograft Mouse Model. K. IGARASHI, K. KAWAGUCHI, T. KIYUNA, K. MIYAKE, T. HIGUCHI, N. YAMAMOTO, K. HAYASHI, H. KIMURA, S. MIWA, S.R. SINGH, H. TSUCHIYA, R.M. HOFFMAN (<i>San Diego, CA; Frederick, MD, USA; Kanazawa, Japan</i>).....	351
NONO Is a Negative Regulator of <i>SOX2</i> Promoter. S. LIANG, H. TAKAHASHI, T. HIROSE, Y. KURAMITSU, S. HATAKEYAMA, H. YOSHIYAMA, R. WANG, J.-I. HAMADA, H. IIZASA (<i>Dalian, PR China; Hokkaido; Shimane; Sapporo; Yokohama, Japan</i>).....	359
Lys05 – A Promising Autophagy Inhibitor in the Radiosensitization Battle: Phosphoproteomic Perspective. M. ONDREJ, L. CECHAKOVA, I. FABRIK, J. KLIMENTOVA, A. TICHY (<i>Hradec Kralove, Czech Republic</i>).....	369
Fusion of the <i>COL4A5</i> Gene With <i>NR2F2-AS1</i> in a Hemangioma Carrying a t(X;15)(q22;q26) Chromosomal Translocation. I. PANAGOPOULOS, L. GORUNOVA, I. LOBMAIER, K. ANDERSEN, M. LUND-IVERSEN, F. MICCI, S. HEIM (<i>Oslo, Norway</i>).....	383

Chromobox 2 Expression Predicts Prognosis After Curative Resection of Oesophageal Squamous Cell Carcinoma. S. UEDA, M. KANDA, Y. SATO, H. BABA, S. NAKAMURA, K. SAWAKI, D. SHIMIZU, S. MOTOYAMA, T. FUJII, Y. KODERA, S. NOMOTO (<i>Nagoya; Akita; Toyama, Japan</i>)	391
Microarray-based Analysis of Genes, Transcription Factors, and Epigenetic Modifications in Lung Cancer Exposed to Nitric Oxide. A. MAIUTHED, O. PRAKHONGCHEEP, P. CHANVORACHOTE (<i>Bangkok, Thailand</i>)	401
Targeted Sequencing of Circulating Cell Free DNA Can Be Used to Monitor Therapeutic Efficacy of Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer Patients. C.-C. CHIOU, C.-L. WANG, J.-D. LUO, C.-Y. LIU, H.-W. KO, C.-T. YANG (<i>Taoyuan, Taiwan, ROC; New York, NY, USA</i>)	417
Long Noncoding RNA <i>ANROC</i> on the <i>INK4</i> Locus Functions to Suppress Cell Proliferation. Y. KOTAKE, T. TSURUDA (<i>Fukuoka, Japan</i>)	425
Association of Relative Leucocyte Telomere Length and Gene Single Nucleotide Polymorphisms (<i>TERT, TRF1, TNKS2</i>) in Laryngeal Squamous Cell Carcinoma. P. VAICIULIS, R. LIUTKEVICIENE, V. LIUTKEVICIUS, A. VILKEVICIUTE, G. GEDVILAITE, V. ULOZA (<i>Kaunas, Lithuania</i>)	431

Number 5, September-October

Reviews

Circulating Tumor DNA in Biliary Tract Cancer: Current Evidence and Future Perspectives. A. RIZZO, A.D. RICCI, S. TAVOLARI, G. BRANDI (<i>Bologna, Italy</i>)	441
Micro RNAs and Corresponding Targets Involved in Metastasis of Colorectal Cancer in Preclinical <i>In Vivo</i> Models. U.H. WEIDLE, U. BRINKMANN, S. AUSLAENDER (<i>Penzberg, Germany</i>)	453

Experimental Studies

Whole-transcriptome Analysis of Fully Viable Energy Efficient Glycolytic-null Cancer Cells Established by Double Genetic Knockout of Lactate Dehydrogenase A/B or Glucose-6-Phosphate Isomerase. E. MAZZIO, R. BADISA, N. MACK, S. CASSIM, M. ZDRALEVIC, J. POUYSSEGUR, K.F.A. SOLIMAN (<i>Tallahassee, FL, USA; Monaco, Monaco; Nice, France</i>)	469
Recurrent Fusion of the GRB2 Associated Binding Protein 1 (<i>GAB1</i>) Gene With ABL Proto-oncogene 1 (<i>ABL1</i>) in Benign Pediatric Soft Tissue Tumors. I. PANAGOPOULOS, L. GORUNOVA, K. ANDERSEN, S. TAFJORD, M. LUND-IVERSEN, I. LOBMAIER, F. MICCI, S. HEIM (<i>Oslo, Norway</i>)	499
<i>STRA6</i> Expression Serves as a Prognostic Biomarker of Gastric Cancer. S. NAKAMURA, M. KANDA, D. SHIMIZU, K. SAWAKI, C. TANAKA, N. HATTORI, M. HAYASHI, S. YAMADA, G. NAKAYAMA, K. OMAE, M. KOIKE, Y. KODERA (<i>Nagoya; Fukushima, Japan</i>)	509
Combination of ERK2 and STAT3 Inhibitors Promotes Anticancer Effects on Acute Lymphoblastic Leukemia Cells. E. JASEK-GAJDA, H. JURKOWSKA, M. JASIŃSKA, J.A. LITWIN, G.J. LIS (<i>Kraków, Poland</i>)	517
Multisite Tumor Sampling Reveals Extensive Heterogeneity of Tumor and Host Immune Response in Ovarian Cancer. S. LAKIS, V. KOTOULA, G.-A. KOLIOU, I. EFSTRATIOU, S. CHRISAFI, A. PAPANIKOLAOU, P. ZEBEKAKIS, G. FOUNTZILAS (<i>Thessaloniki; Athens, Greece; Limassol, Cyprus</i>)	529
Characterization of Kinase Expression Related to Increased Migration of PC-3M Cells Using Global Comparative Phosphoproteome Analysis. Y. GAO, Y.-S. HA, T.G. KWON, Y.-C. CHO, S. LEE, J.N. LEE (<i>Daegu; Gwangju, Republic of Korea</i>)	543

Fusion of the Lumican (<i>LUM</i>) Gene With the Ubiquitin Specific Peptidase 6 (<i>USP6</i>) Gene in an Aneurysmal Bone Cyst Carrying a t(12;17)(q21;p13) Chromosome Translocation. I. PANAGOPOULOS, L. GORUNOVA, K. ANDERSEN, I. LOBMAIER, M. LUND-IVERSEN, F. MICCI, S. HEIM (<i>Oslo, Norway</i>).....	555
Cytogenetic and Molecular Study of an Adult Sclerosing Rhabdomyosarcoma of the Extremity: <i>MYOD1</i> -mutation and Clonal Evolution. L. GORUNOVA, B. BJERKEHAGEN, F. MICCI, S. HEIM, I. PANAGOPOULOS (<i>Oslo, Norway</i>).....	563
The Significant Interaction of Excision Repair Cross-complementing Group 1 Genotypes and Smoking to Lung Cancer Risk. L.-H. CHEN, T.-C. SHEN, C.-H. LI, K.-L. CHIU, Y.-C. HSIAU, Y.-C. WANG, C.-L. GONG, Z.-H. WANG, W.-S. CHANG, C.-W. TSAI, T.-C. HSIA, D.-T. BAU (<i>Taichung, Taiwan, ROC</i>).....	571
Expression Patterns of CD44 and AREG Under Treatment With Selective Tyrosine Kinase Inhibitors in HPV+ and HPV– Squamous Cell Carcinoma. B. KANSY, C. ADERHOLD, L. HUBER, S. LUDWIG, R. BIRK, A. LAMMERT, S. LANG, N. ROTTER, B. KRAMER (<i>Essen; Mannheim; Marburg, Germany</i>).....	579
Platinum Drug Sensitivity Polymorphisms in Stage III Non-small Cell Lung Cancer With Invasion of Mediastinal Lymph Nodes. A. NASTASE, A. LUPO, V. LASZLO, D. DAMOTTE, S. DIMA, E. CANNY, M. ALIFANO, I. POPESCU, W. KLEPETKO, M. GRIGOROIU (<i>Bucharest, Romania; Paris, France; Vienna, Austria</i>).....	587
<i>Clinical Studies</i>	
Influence of Concurrent Mutations on Overall Survival in EGFR-mutated Non-small Cell Lung Cancer. M. CHEVALLIER, P. TSANTOULIS, A. ADDEO, A. FRIEDLAENDER (<i>Geneva, Switzerland</i>).....	597
Association of miR-125b, miR-17 and let-7c Dysregulations With Response to Anti-epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With Metastatic Colorectal Cancer. O. FIALA, O. SOREJS, P. HOSEK, V. LISKA, O. VYCITAL, J. BRUHA, R. KUCERA, O. TOPOLCAN, J. FINEK, D. MACECKOVA, P. PITULE (<i>Pilsen, Czech Republic</i>).....	605
hTERT Protein Expression in Cytoplasm and Nucleus and its Association With HPV Infection in Patients With Cervical Cancer. P. MORENO-ACOSTA, M. MOLANO, N. MORALES, J. ACOSTA, C. GONZÁLEZ-PRIETO, D. MAYORGA, L. BUITRAGO, O. GAMBOA, J.C. MEJÍA, J. CASTRO, A. ROMERO-ROJAS, S. ESPENEL, G.L. MURRAY, S.M. GARLAND, A. VALLARD, N. MAGNÉ (<i>Bogotá, Colombia; Melbourne, Australia; Saint-Priest en Jarez, France; Parkville, VIC, Australia</i>).....	615
Clinicopathological and Molecular Differences Between Gastric-type Mucinous Carcinoma and Usual-type Endocervical Adenocarcinoma of the Uterine Cervix. H. JUNG, G.E. BAE, H.M. KIM, H.-S. KIM (<i>Seoul; Goyang; Daejeon, Republic of Korea</i>).....	627
Copy Number Alterations in Papillary Thyroid Carcinomas: Does Loss of <i>SESN2</i> Have a Role in Age-related Different Prognoses? D.C.N. DE ALMEIDA, M.P.C. DE SOUZA, C.K.N. AMORIM, J.H. DA SILVA MAUÉS, F.D.E. SANTO SAGICA, C.A. MOREIRA-NUNES, E.H.C. DE OLIVEIRA (<i>Belém; Ananindeua, PA; Fortaleza, CE, Brazil</i>).....	643
Erratum.....	649

Number 6, November-December

Review

Micro RNAs Promoting Growth and Metastasis in Preclinical <i>In Vivo</i> Models of Subcutaneous Melanoma. U.H. WEIDLE, S. AUSLÄNDER, U. BRINKMANN (<i>Penzberg, Germany</i>).....	651
---	-----

Experimental Studies

Differential Proteomic Analysis of Hepatocellular Carcinomas from *Ppp2r5d* Knockout Mice and Normal (Knockout) Livers. C. LAMBRECHT, G.B. FERREIRA, J.D. OMELLA, L. LIBBRECHT, R. DE VOS, R. DERUA, C. MATHIEU, L. OVERBERGH, E. WAELEKENS, V. JANSSENS (*Leuven; Brussels, Belgium*)..... 669

TIP60/P400/H4K12ac Plays a Role as a Heterochromatin Back-up Skeleton in Breast Cancer. M. IDRISOU, T. BOISNIER, A. SANCHEZ, F.Z.H. KHOUFAF, F. PENAULT-LLORCA, Y.-J. BIGNON, D. BERNARD-GALLON (*Clermont-Ferrand, France*) 687

Deletion of Histone Methyltransferase G9a Suppresses Mutant Kras-driven Pancreatic Carcinogenesis. H. KATO, K. TATEISHI, H. FUJIWARA, H. IJICHI, K. YAMAMOTO, T. NAKATSUKA, M. KAKIUCHI, M. SANO, Y. KUDO, Y. HAYAKAWA, H. NAKAGAWA, Y. TANAKA, M. OTSUKA, Y. HIRATA, M. TACHIBANA, Y. SHINKAI, K. KOIKE (*Tokyo; Osaka; Saitama, Japan*) 695

Senescence of Normal Human Fibroblasts Relates to the Expression of Ionotropic Glutamate Receptor GluR6/Grik2. V.K. ZHAWAR, R.P. KANDPAL, R.S. ATHWAL (*Philadelphia, PA; Pomona, CA, USA*) 707

The KDR (VEGFR-2) Genetic Polymorphism Q472H and c-KIT Polymorphism M541L Are Associated With More Aggressive Behaviour in Astrocytic Gliomas. N. ZAMAN, S.S. DASS, P.D. PARCQ, S. MACMAHON, L. GALLAGHER, L. THOMPSON, J.S. KHORASHAD, C. LIMBÄCK-STANIC (*London, UK*) 715

Stem-like Cells from Invasive Breast Carcinoma Cell Line MDA-MB-231 Express a Distinct Set of Eph Receptors and Ephrin Ligands. M. LUCERO, J. THIND, J. SANDOVAL, S. SENAATI, B. JIMENEZ, R.P. KANDPAL (*Pomona, CA, USA*) 729

The Association Between the Genetic *VDR* SNP c.907+75C>T and Prostate Cancer Risk Is Modified by Tanning Potential. D.A. BEYENE, M.R. DAREMIPOURAN, V. APPREY, T. NAAB, O.O. KASSIM, R.L. COPELAND, Y.M. KANAAN (*Washington, DC, USA*) 739

Expression of Pregnancy Up-regulated Non-ubiquitous Calmodulin Kinase (PNCK) in Hepatocellular Carcinoma. Y.A. CHO, S. CHOI, S. PARK, C.-K. PARK, S.Y. HA (*Seoul; Anyang, Republic of Korea*) 747

Normal Mouse Brain Proteome II: Analysis of Brain Regions by High-resolution Mass Spectrometry. A.G. KOROVESI, A.K. ANAGNOSTOPOULOS, V. PIERROS, D.J. STRAVOPODIS, G.TH. TSANGARIS (*Athens, Greece*) 757

lincRNA-RP11400K9.4 Regulates Cell Survival and Migration of Breast Cancer Cells. M.A. FERNÁNDEZ-ROJAS, J. MELENDEZ-ZAJGLA, V.M. LAGUNAS (*México City, México*) 769

Gigantol Targets MYC for Ubiquitin-proteasomal Degradation and Suppresses Lung Cancer Cell Growth. N. LOSUWANNARAK, S. ROYTRAKUL, P. CHANVORACHOTE (*Bangkok; Pathumthani, Thailand*) 781

Comparison of Benign and Malignant Pilomatricomas Using Whole-exome Sequencing. M.-K. YEO, G.E. BAE (*Daejeon, Republic of Korea*) 795

Targeted Genomic Sequencing Reveals Different Evolutionary Patterns Between Locally and Distally Recurrent Glioblastomas. N. YOON, H.-S. KIM, J.W. LEE, E.-J. LEE, L.-S. MAENG, W.S. YOON (*Incheon; Seoul, Republic of Korea*) 803

Clinical Studies

Atypical Mesonephric Hyperplasia of the Uterus Harbors Pathogenic Mutation of Kirsten Rat Sarcoma 2 Viral Oncogene Homolog (*KRAS*) and Gain of Chromosome 1q. H. KIM, N. YOON, H.Y. WOO, E.-J. LEE, S.-I. DO, K. NA, H.-S. KIM (*Seoul; Incheon, Republic of Korea*) 813

Genetic Analysis Identifies the Role of *HLF* in Renal Cell Carcinoma. C.-Y. HUANG, S.-P. HUANG, Y.-M. HSUEH, L.-C. CHEN, T.-L. LU, B.-Y. BAO (*Taipei; Kaohsiung; New Taipei City; Taichung, Taiwan, ROC*)..... 827

Index 835

Subject Index

(Figures refer to page numbers)

- 2D-DIGE, HCC, PP2A, tumor suppressor, ppp2r5d, b56δ subunit, biomarker, mouse model, hepatocarcinogenesis, fibrinogen, liver, proteomics, 669
- 3Pt, osteosarcoma, cisplatin-resistant, platinum complex, efficacy, PDOX, 217
- ABL1*, benign pediatric soft tissue tumors, pediatric, soft tissue perineurioma, chromosome translocation, *GABI*, *GABI- ABL1* fusion gene, der(4)t(4;9)(q31;q34), 499
- ACGH, papillary thyroid cancer, deletion, *SESN2*, senescence, 643
- Acute lymphoblastic leukemia, case-control study, genotype, miR146a, polymorphism, Taiwan, 175
- Adipokines, *BRCA* mutation, *ADIPOQ* polymorphism, *BRCA*-associated cancer, 301
- ADIPOQ* polymorphism, *BRCA* mutation, adipokines, *BRCA*-associated cancer, 301
- Adult sclerosing rhabdomyosarcoma, *mYOD1*-mutation, chromosome aberrations, clonal evolution, 563
- Afatinib, CD44, *AREG*, head and neck squamous cell carcinoma, drug resistance, nilotinib, dasatinib, erlotinib, gefitinib, 579
- African American men, prostate cancer, vitamin D, vitamin D receptor gene, single nucleotide polymorphism, 739
- Age, genotype, stromal TIL density, co-mutation, NGS, 181
- ALL, ERK, *STAT3*, apoptosis, cell cycle, ROS, 517
- Aneurysmal bone cyst, chromosome translocation, *LUM*, *USP6*, *LUM-USP6* fusion gene, 555
- Antagomirs, intra-hepatic and distant metastasis, functional reconstitution of miRs, *in vivo* metastasis models, miR-mimetics, metastasis-related *in vivo* models, prognostic correlations, subcutaneous implantation, tail vein injection, therapeutic modalities, therapeutic targets, review, 1
- Antisense-oligonucleotides, microRNA delivery, microRNA mimetics, locked nucleic acids, treatment resistance, multiple myeloma, review, 321
- Apoptosis, ERK, *STAT3*, cell cycle, ROS, ALL, 517
- AREG*, CD44, head and neck squamous cell carcinoma, drug resistance, afatinib, nilotinib, dasatinib, erlotinib, gefitinib, 579
- Artificial intelligence, glioma, microvascular proliferation, *KIT*, *KDR*, polymorphism, next-generation sequencing, 715
- Atypical mesonephric hyperplasia, uterus, cervix, Kirsten rat sarcoma 2 viral oncogene homolog (*KRAS*) mutation, Chromosome 1q gain, 813
- Autophagy, phosphoproteomics, lung cancer, inhibitor, *lys05*, 369
- B56δ subunit, HCC, PP2A, tumor suppressor, ppp2r5d, 2D-DIGE, biomarker, mouse model, hepatocarcinogenesis, fibrinogen, liver, proteomics, 669
- Benign pediatric soft tissue tumors, pediatric, soft tissue perineurioma, chromosome translocation, *GABI*, *ABL1*, *GABI- ABL1* fusion gene, der(4)t(4;9)(q31;q34), 499
- Biliary tract cancer, liquid biopsy, cholangiocarcinoma, ctDNA, cfDNA, review, 441
- Biodistribution, bioluminescence, colorectal cancer, pEG-liposome, pharmacokinetics, micro positron emission tomography, 61
- Bioinformatics, nitric oxide, microarrays, transcription factors, epigenetic modifications, lung cancer, 401
- Bioinformatics, pediatric astrocytic tumors, exome analysis, DNA mutations, chromosomal abnormalities, 117
- Bioluminescence, biodistribution, colorectal cancer, pEG-liposome, pharmacokinetics, micro positron emission tomography, 61
- Biomarker, cell cycle, prostate cancer, recurrence, *YWHAZ*, 209
- Biomarker, chromobox 2 (*CBX2*), oesophageal squamous cell carcinoma, recurrence, 391
- Biomarker, gastric cancer, *STRA6*, recurrence, prognosis, 509
- Biomarker, HCC, PP2A, tumor suppressor, ppp2r5d, b56δ subunit, 2D-DIGE, mouse model, hepatocarcinogenesis, fibrinogen, liver, proteomics, 669
- Biomarker, *KIF15*, hepatocellular carcinoma, intracellular transporter, inflammatory monocyte, 141
- Biomarker, *PCTK1/CDK16*, non-small cell lung cancer, circulating mRNA, 91
- Biomarkers, gastric cancer, chemoradiotherapy, 277
- Biomarkers, malignant pleural mesothelioma, proteomic analysis, secretome, proteome, cell lines, 225
- Biomarkers, proteomic profiling, head and neck squamous cell carcinoma, recurrence and metastasis, predictive model, 259
- BIRC3*, breast cancer, lincRNA-RP11400K9.4, cell survival, migration, 769
- Bone morphogenetic protein, gremlin1, gastric cancer, 49
- Brain, glioblastoma, recurrence, evolutionary pattern, targeted sequencing, 803
- Brain, proteomics, proteome, high resolution mass spectrometry, nanoLC-MS/MS, tandem mass spectrometry, mouse, cerebral cortex, olfactory bulb, hippocampus, hypothalamus, midbrain, cerebellum, medulla, normal mouse brain, normal adult mouse brain, 757
- BRCA* mutation, adipokines, *ADIPOQ* polymorphism, *BRCA*-associated cancer, 301
- BRCA*-associated cancer, *BRCA* mutation, adipokines, *ADIPOQ* polymorphism, 301

- BRD4, mantle cell lymphoma, chIP-Seq, super-enhancer, drug resistance, 77
- Breast cancer tumor, TIP60, h4K12ac, P400, heterochromatin, euchromatin, 687
- Breast cancer, lincRNA-RP11400K9.4, cell survival, migration, BIRC3, 769
- Breast cancer, prognosis, pluripotency, cell cycle, 169
- Breast carcinoma, stem cells, stem-like cells, triple-negative breast cancer cells, eph receptors, ephrin ligands, CD44+/CD24- cells, MDA-MB-231 cells, 729
- Breast cancer, SOX2, negative regulator, transcription factor, cancer stem cell, 359
- Calmodulin, hepatocellular carcinoma, prognosis, PNCK, EGFR, 747
- Cancer stem cell, SOX2, negative regulator, transcription factor, breast cancer, 359
- Cancer, mediterranean diet, epigenetic, nutraceuticals, nutrigenomics, review, 335
- Cancer, metabolism, LDHA, LDHB, GPI, Warburg effect, genes, 469
- Cancer, senescence, normal fibroblasts, gluR6, grik2, glutamate receptor, 707
- Carcinogenesis, panIN, PDAC, epigenetics, chromatin accessibility, 695
- Carcinoma, genomics, dementia, the Cancer Genome Atlas, prostate, 271
- Case-control study, acute lymphoblastic leukemia, genotype, miR146a, polymorphism, Taiwan, 175
- CD44, AREG, head and neck squamous cell carcinoma, drug resistance, afatinib, nilotinib, dasatinib, erlotinib, gefitinib, 579
- CD44+/CD24- cells, breast carcinoma, stem cells, stem-like cells, triple-negative breast cancer cells, eph receptors, ephrin ligands, MDA-MB-231 cells, 729
- CDK inhibitor, *iNK4* locus, long noncoding RNA, cell cycle, cyclinB1, 425
- Cell cycle, ERK, STAT3, apoptosis, ROS, ALL, 517
- Cell cycle, *iNK4* locus, long noncoding RNA, cyclinB1, CDK inhibitor, 425
- Cell cycle, prognosis, pluripotency, breast cancer, 169
- Cell cycle, prostate cancer, recurrence, YWHAZ, biomarker, 209
- Cell lines, malignant pleural mesothelioma, biomarkers, proteomic analysis, secretome, proteome, 225
- Cell proliferation, gigantol, *Dendrobium draconis*, MYC, proteomics, lung cancer, 781
- Cell survival, breast cancer, lincRNA-RP11400K9.4, migration, BIRC3, 769
- Cerebellum, proteomics, proteome, high resolution mass spectrometry, nanoLC-MS/MS, tandem mass spectrometry, mouse, brain, cerebral cortex, olfactory bulb, hippocampus, hypothalamus, midbrain, medulla, normal mouse brain, normal adult mouse brain, 757
- Cerebral cortex, proteomics, proteome, high resolution mass spectrometry, nanoLC-MS/MS, tandem mass spectrometry, mouse, brain, olfactory bulb, hippocampus, hypothalamus, midbrain, cerebellum, medulla, normal mouse brain, normal adult mouse brain, 757
- Cervical cancer, *hTERT* protein expression, *hTERT* localization, nuclear *hTERT*, cytoplasmic *hTERT*, *hTERT* methylation, HPV, 615
- Cervix, uterus, atypical mesonephric hyperplasia, Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) mutation, Chromosome 1q gain, 813
- Cervix, uterus, usual-type endocervical adenocarcinoma, gastric-type mucinous carcinoma, immunohistochemistry, targeted sequencing, 627
- Cetuximab, colorectal cancer, panitumumab, chemotherapy, microRNA, miR-125b, miR-17, let-7c, 605
- cfDNA, liquid biopsy, biliary tract cancer, cholangiocarcinoma, ctDNA, review, 441
- Chemoradiotherapy, biomarkers, gastric cancer, 277
- Chemoradiotherapy, rectal cancer, microRNA, prediction, 249
- Chemotherapy, colorectal cancer, cetuximab, panitumumab, microRNA, miR-125b, miR-17, let-7c, 605
- ChIP-Seq, mantle cell lymphoma, BRD4, super-enhancer, drug resistance, 77
- Cholangiocarcinoma, liquid biopsy, biliary tract cancer, ctDNA, cfDNA, review, 441
- Chondroid syringoma, *PLAG1*, fusion genes, *NDRG1-PLAG1*, *TRPS1-PLAG1*, Chromosome 8, 237
- Chromatin accessibility, carcinogenesis, panIN, PDAC, epigenetics, 695
- Chromobox 2 (*CBX2*), biomarker, oesophageal squamous cell carcinoma, recurrence, 391
- Chromosomal abnormalities, pediatric astrocytic tumors, exome analysis, DNA mutations, bioinformatics, 117
- Chromosome 1q gain, uterus, cervix, atypical mesonephric hyperplasia, Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) mutation, 813
- Chromosome 8, chondroid syringoma, *PLAG1*, fusion genes, *NDRG1-PLAG1*, *TRPS1-PLAG1*, 237
- Chromosome aberrations, adult sclerosing rhabdomyosarcoma, mYOD1-mutation, clonal evolution, 563
- Chromosome translocation t(14;21)(q11;q22), pediatric T-cell lymphoblastic lymphoma, *TRA/TRD* enhancer, *OLIG1* expression, *OLIG2* expression, unfavorable prognosis, 41
- Chromosome translocation, aneurysmal bone cyst, LUM, USP6, LUM-USP6 fusion gene, 555
- Chromosome translocation, benign pediatric soft tissue tumors, pediatric, soft tissue perineurioma, *GAB1*, *ABL1*, *GAB1-ABL1* fusion gene, der(4)t(4;9)(q31;q34), 499
- Chromosome translocation, hemangioma, cytogenetics, karyotype, rNasequencing, *COL4A5*, *NR2F2-AS1*, fusion gene, *COL4A5-NR2F2-AS1*, 383

- Circadian rhythm, renal cell carcinoma, single nucleotide polymorphism, overall survival, metastasis-free survival, 827
- Circulating mRNA, PCTK1/CDK16, biomarker, non-small cell lung cancer, 91
- Circulating tumor DNA, EGFR mutation, monitoring markers, non-small cell lung cancer, 417
- Cisplatin-resistant, osteosarcoma, platinum complex, efficacy, 3Pt, PDOX, 217
- Cisplatin, osteosarcoma, pioglitazone, drug resistance, PDOX, pPAR γ , 35
- Clonal evolution, vulvar cancer, vulvar neoplasms, squamous cell carcinoma, *Lichen sclerosus*, vulvar *Lichen sclerosus*, differentiated vulvar intraepithelial neoplasia, 151
- Clonal evolution, adult sclerosing rhabdomyosarcoma, mYOD1-mutation, chromosome aberrations, 563
- CMG helicase uncoupling, replication stress, g-quadruplex, i-motif, 101
- Co-mutation, age, genotype, stromal TIL density, NGS, 181
- Co-mutations, EGFR, concurrent mutations, NSCLC, osimertinib, resistance, 597
- COL4A5-NR2F2-AS1*, hemangioma, cytogenetics, karyotype, rNasequencing, chromosome translocation, *COL4A5, NR2F2-AS1*, fusion gene, 383
- COL4A5*, hemangioma, cytogenetics, karyotype, rNasequencing, chromosome translocation, *NR2F2-AS1*, fusion gene, *COL4A5-NR2F2-AS1*, 383
- Colorectal cancer, biodistribution, bioluminescence, pEG-liposome, pharmacokinetics, micro positron emission tomography, 61
- Colorectal cancer, cetuximab, panitumumab, chemotherapy, microRNA, miR-125b, miR-17, let-7c, 605
- Colorectal cancer, lipopolysaccharide, miR-140, cytokines, TRAF6, 23
- Colorectal cancer, pazopanib, orthotopic tumor, lymph node metastasis, lymphangiogenesis, nude mice, 131
- Concurrent mutations, EGFR, co-mutations, NSCLC, osimertinib, resistance, 597
- ctDNA, liquid biopsy, biliary tract cancer, cholangiocarcinoma, cfDNA, review, 441
- CTNNB1, FGFR4, malignant, mutation, pilomatricoma, whole-exome sequencing, 795
- CyclinB1, *iNK4* locus, long noncoding RNA, cell cycle, CDK inhibitor, 425
- Cytogenetics, hemangioma, karyotype, rNasequencing, chromosome translocation, *COL4A5, NR2F2-AS1*, fusion gene, *COL4A5-NR2F2-AS1*, 383
- Cytogenetics, osteoblastoma, *FOS*, fusion gene, *FOS-ANKH, FOS-RUNX2*, RNA sequencing, 161
- Cytokines, colorectal cancer, lipopolysaccharide, miR-140, TRAF6, 23
- Cytoplasmic hTERT, cervical cancer, hTERT protein expression, hTERT localization, nuclear hTERT, hTERT methylation, HPV, 615
- Dasatinib, CD44, AREG, head and neck squamous cell carcinoma, drug resistance, afatinib, nilotinib, erlotinib, gefitinib, 579
- Dedifferentiated liposarcoma, patient-derived orthotopic xenograft, PDOX, eribulin, regression, doxorubicin resistance, 351
- Deletion, papillary thyroid cancer, aCGH, SESN2, senescence, 643
- Dementia, genomics, the Cancer Genome Atlas, prostate, carcinoma, 271
- Dendrobium draconis*, gigantol, MYC, proteomics, cell proliferation, lung cancer, 781
- Der(4)t(4;9)(q31;q34), benign pediatric soft tissue tumors, pediatric, soft tissue perineurioma, chromosome translocation, *GABI, ABL1, GABI- ABL1* fusion gene, 499
- Diagnostics, prostate cancer, quantitative proteomics, SRM, markers, 195
- Differentiated vulvar intraepithelial neoplasia, vulvar cancer, vulvar neoplasms, squamous cell carcinoma, *Lichen sclerosus*, vulvar *Lichen sclerosus*, clonal evolution, 151
- DNA mutations, pediatric astrocytic tumors, exome analysis, chromosomal abnormalities, bioinformatics, 117
- Doxorubicin resistance, patient-derived orthotopic xenograft, PDOX, eribulin, regression, dedifferentiated liposarcoma, 351
- Drug resistance, CD44, AREG, head and neck squamous cell carcinoma, afatinib, nilotinib, dasatinib, erlotinib, gefitinib, 579
- Drug resistance, mantle cell lymphoma, BRD4, chIP-Seq, super-enhancer, 77
- Drug resistance, osteosarcoma, pioglitazone, cisplatin, PDOX, pPAR γ , 35
- Efficacy, osteosarcoma, cisplatin-resistant, platinum complex, 3Pt, PDOX, 217
- EGFR mutation, circulating tumor DNA, monitoring markers, non-small cell lung cancer, 417
- EGFR, co-mutations, concurrent mutations, NSCLC, osimertinib, resistance, 597
- EGFR, hepatocellular carcinoma, prognosis, PNCK, calmodulin, 747
- Eph receptors, breast carcinoma, stem cells, stem-like cells, triple-negative breast cancer cells, ephrin ligands, CD44+/CD24- cells, MDA-MB-231 cells, 729
- Ephrin ligands, breast carcinoma, stem cells, stem-like cells, triple-negative breast cancer cells, eph receptors, CD44+/CD24- cells, MDA-MB-231 cells, 729
- Epigenetic modifications, nitric oxide, microarrays, bioinformatics, transcription factors, lung cancer, 401
- Epigenetic, mediterranean diet, nutraceuticals, nutrigenomics, cancer, review, 335

- Epigenetics, carcinogenesis, panIN, PDAC, chromatin accessibility, 695
- Epithelial ovarian cancer, tumor marker, TRPV1, PTEN, 309
- Epithelial-mesenchymal transition (EMT), invasion and migration, *in vivo* metastasis-related models, microRNA (miR), miR-related therapeutic agents, liver metastasis, oncogenic signaling pathways, tGFβ signaling, tumor- and -metastasis suppressors, review, 453
- Epithelial-mesenchymal transition, metastasis models, microRNA editing, microRNA inhibition and reconstitution of function, migration, invasion and proliferation, therapeutic targets, review, 651
- ERCC1, genotype, lung cancer, polymorphism, smoking, Taiwan, 571
- Eribulin, patient-derived orthotopic xenograft, PDOX, regression, doxorubicin resistance, dedifferentiated liposarcoma, 351
- ERK, STAT3, apoptosis, cell cycle, ROS, ALL, 517
- Erlotinib, CD44, AREG, head and neck squamous cell carcinoma, drug resistance, afatinib, nilotinib, dasatinib, gefitinib, 579
- Euchromatin, breast cancer tumor, TIP60, h4K12ac, P400, heterochromatin, 687
- Evolutionary pattern, brain, glioblastoma, recurrence, targeted sequencing, 803
- Exome analysis, pediatric astrocytic tumors, DNA mutations, chromosomal abnormalities, bioinformatics, 117
- FGFR4, CTNNB1, malignant, mutation, pilomatricoma, whole-exome sequencing, 795
- Fibrinogen, HCC, PP2A, tumor suppressor, ppp2r5d, b56δ subunit, 2D-DIGE, biomarker, mouse model, hepatocarcinogenesis, liver, proteomics, 669
- FOS-ANKH*, osteoblastoma, *FOS*, fusion gene, *FOS-RUNX2*, cytogenetics, RNA sequencing, 161
- FOS-RUNX2*, osteoblastoma, *FOS*, fusion gene, *FOS-ANKH*, cytogenetics, RNA sequencing, 161
- FOS*, osteoblastoma, fusion gene, *FOS-ANKH*, *FOS-RUNX2*, cytogenetics, RNA sequencing, 161
- Functional reconstitution of miRs, antagomirs, intra-hepatic and distant metastasis, *in vivo* metastasis models, miR-mimetics, metastasis-related *in vivo* models, prognostic correlations, subcutaneous implantation, tail vein injection, therapeutic modalities, therapeutic targets, review, 1
- Fusion gene, hemangioma, cytogenetics, karyotype, rNasequencing, chromosome translocation, *COL4A5*, *NR2F2-AS1*, *COL4A5-NR2F2-AS1*, 383
- Fusion gene, osteoblastoma, *FOS*, *FOS-ANKH*, *FOS-RUNX2*, cytogenetics, RNA sequencing, 161
- Fusion genes, chondroid syringoma, *PLAG1*, *NDRG1-PLAG1*, *TRPS1-PLAG1*, Chromosome 8, 237
- G-quadruplex, CMG helicase uncoupling, replication stress, i-motif, 101
- GABI- ABL1* fusion gene, benign pediatric soft tissue tumors, pediatric, soft tissue perineurioma, chromosome translocation, *GABI*, *ABL1*, der(4)t(4;9)(q31;q34), 499
- GABI*, benign pediatric soft tissue tumors, pediatric, soft tissue perineurioma, chromosome translocation, *ABL1*, *GABI- ABL1* fusion gene, der(4)t(4;9)(q31;q34), 499
- Gastric cancer, biomarkers, chemoradiotherapy, 277
- Gastric cancer, gremlin1, bone morphogenetic protein, 49
- Gastric cancer, *STRA6*, recurrence, prognosis, biomarker, 509
- Gastric-type mucinous carcinoma, uterus, cervix, usual-type endocervical adenocarcinoma, immunohistochemistry, targeted sequencing, 627
- Gefitinib, CD44, AREG, head and neck squamous cell carcinoma, drug resistance, afatinib, nilotinib, dasatinib, erlotinib, 579
- Gene polymorphisms, leucocyte telomeres, *TERT*, *TRF1*, *TNKS2*, laryngeal carcinoma, 431
- Genes, cancer, metabolism, LDHA, LDHB, GPI, Warburg effect, 469
- Genomics, dementia, the Cancer Genome Atlas, prostate, carcinoma, 271
- Genotype, acute lymphoblastic leukemia, case-control study, miR146a, polymorphism, Taiwan, 175
- Genotype, age, stromal TIL density, co-mutation, NGS, 181
- Genotype, ERCC1, lung cancer, polymorphism, smoking, Taiwan, 571
- Gigantol, *Dendrobium draconis*, MYC, proteomics, cell proliferation, lung cancer, 781
- Glioblastoma, brain, recurrence, evolutionary pattern, targeted sequencing, 803
- Glioma, microvascular proliferation, KIT, KDR, artificial intelligence, polymorphism, next-generation sequencing, 715
- GluR6, senescence, normal fibroblasts, grik2, glutamate receptor, cancer, 707
- Glutamate receptor, senescence, normal fibroblasts, gluR6, grik2, cancer, 707
- GPI, cancer, metabolism, LDHA, LDHB, Warburg effect, genes, 469
- Gremlin1, bone morphogenetic protein, gastric cancer, 49
- Grik2, senescence, normal fibroblasts, gluR6, glutamate receptor, cancer, 707
- H4K12ac, breast cancer tumor, TIP60, P400, heterochromatin, euchromatin, 687
- HCC, PP2A, tumor suppressor, ppp2r5d, b56δ subunit, 2D-DIGE, biomarker, mouse model, hepatocarcinogenesis, fibrinogen, liver, proteomics, 669

- Head and neck squamous cell carcinoma, CD44, AREG, drug resistance, afatinib, nilotinib, dasatinib, erlotinib, gefitinib, 579
- Head and neck squamous cell carcinoma, proteomic profiling, recurrence and metastasis, biomarkers, predictive model, 259
- Hemangioma, cytogenetics, karyotype, rNAsequencing, chromosome translocation, *COL4A5*, *NR2F2-AS1*, fusion gene, *COL4A5-NR2F2-AS1*, 383
- Hepatocarcinogenesis, HCC, PP2A, tumor suppressor, ppp2r5d, b56δ subunit, 2D-DIGE, biomarker, mouse model, fibrinogen, liver, proteomics, 669
- Hepatocellular carcinoma, *KIF15*, intracellular transporter, inflammatory monocyte, biomarker, 141
- Hepatocellular carcinoma, prognosis, PNCK, EGFR, calmodulin, 747
- Heterochromatin, breast cancer tumor, TIP60, h4K12ac, P400, euchromatin, 687
- High resolution mass spectrometry, proteomics, proteome, nanoLC-MS/MS, tandem mass spectrometry, mouse, brain, cerebral cortex, olfactory bulb, hippocampus, hypothalamus, midbrain, cerebellum, medulla, normal mouse brain, normal adult mouse brain, 757
- Hippocampus, proteomics, proteome, high resolution mass spectrometry, nanoLC-MS/MS, tandem mass spectrometry, mouse, brain, cerebral cortex, olfactory bulb, hypothalamus, midbrain, cerebellum, medulla, normal mouse brain, normal adult mouse brain, 757
- HPV, cervical cancer, *hTERT* protein expression, *hTERT* localization, nuclear *hTERT*, cytoplasmic *hTERT*, *hTERT* methylation, 615
- HTERT* protein expression, cervical cancer, *hTERT* localization, nuclear *hTERT*, cytoplasmic *hTERT*, *hTERT* methylation, HPV, 615
- HTERT* localization, cervical cancer, *hTERT* protein expression, nuclear *hTERT*, cytoplasmic *hTERT*, *hTERT* methylation, HPV, 615
- HTERT* methylation, cervical cancer, *hTERT* protein expression, *hTERT* localization, nuclear *hTERT*, cytoplasmic *hTERT*, HPV, 615
- Hypothalamus, proteomics, proteome, high resolution mass spectrometry, nanoLC-MS/MS, tandem mass spectrometry, mouse, brain, cerebral cortex, olfactory bulb, hippocampus, midbrain, cerebellum, medulla, normal mouse brain, normal adult mouse brain, 757
- I-motif, CMG helicase uncoupling, replication stress, g-quadruplex, 101
- Immunohistochemistry, uterus, cervix, usual-type endocervical adenocarcinoma, gastric-type mucinous carcinoma, targeted sequencing, 627
- Immunoreactive subtype, mesenchymal subtype, solid subtype, tILs, tumor stroma, proliferation, 529
- In vivo* metastasis models, antagomirs, intra-hepatic and distant metastasis, functional reconstitution of miRs, miR-mimetics, metastasis-related *in vivo* models, prognostic correlations, subcutaneous implantation, tail vein injection, therapeutic modalities, therapeutic targets, review, 1
- In vivo* metastasis-related models, epithelial-mesenchymal transition (EMT), invasion and migration, microRNA (miR), miR-related therapeutic agents, liver metastasis, oncogenic signaling pathways, tGFβ signaling, tumor- and -metastasis suppressors, review, 453
- Inflammatory monocyte, *KIF15*, hepatocellular carcinoma, intracellular transporter, biomarker, 141
- Inhibitor, phosphoproteomics, lung cancer, autophagy, lys05, 369
- INK4* locus, long noncoding RNA, cell cycle, cyclinB1, CDK inhibitor, 425
- Intra-hepatic and distant metastasis, antagomirs, functional reconstitution of miRs, *in vivo* metastasis models, miR-mimetics, metastasis-related *in vivo* models, prognostic correlations, subcutaneous implantation, tail vein injection, therapeutic modalities, therapeutic targets, review, 1
- Intracellular transporter, *KIF15*, hepatocellular carcinoma, inflammatory monocyte, biomarker, 141
- Invasion and migration, epithelial-mesenchymal transition (EMT), *in vivo* metastasis-related models, microRNA (miR), miR-related therapeutic agents, liver metastasis, oncogenic signaling pathways, tGFβ signaling, tumor- and -metastasis suppressors, review, 453
- Invasion and proliferation, epithelial-mesenchymal transition, metastasis models, microRNA editing, microRNA inhibition and reconstitution of function, migration, therapeutic targets, review, 651
- Karyotype, hemangioma, cytogenetics, rNAsequencing, chromosome translocation, *COL4A5*, *NR2F2-AS1*, fusion gene, *COL4A5-NR2F2-AS1*, 383
- KDR, glioma, microvascular proliferation, KIT, artificial intelligence, polymorphism, next-generation sequencing, 715
- KIF15*, hepatocellular carcinoma, intracellular transporter, inflammatory monocyte, biomarker, 141
- Kinases, metastatic prostate cancer, proteomics, phosphorylation, 543
- Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) mutation, uterus, cervix, atypical mesonephric hyperplasia, Chromosome 1q gain, 813
- KIT, glioma, microvascular proliferation, KDR, artificial intelligence, polymorphism, next-generation sequencing, 715
- Laryngeal carcinoma, leucocyte telomeres, *TERT*, *TRF1*, *TNKS2*, gene polymorphisms, 431
- LDHA, cancer, metabolism, LDHB, GPI, Warburg effect, genes, 469

- LDHB, cancer, metabolism, LDHA, GPI, Warburg effect, genes, 469
- Let-7c, colorectal cancer, cetuximab, panitumumab, chemotherapy, microRNA, miR-125b, miR-17, 605
- Leucocyte telomeres, *TERT*, *TRF1*, *TNKS2*, laryngeal carcinoma, gene polymorphisms, 431
- Lichen sclerosus*, vulvar cancer, vulvar neoplasms, squamous cell carcinoma, vulvar *Lichen sclerosus*, differentiated vulvar intraepithelial neoplasia, clonal evolution, 151
- LincRNA-RP11400K9.4, breast cancer, cell survival, migration, BIRC3, 769
- Lipopolysaccharide, colorectal cancer, miR-140, cytokines, TRAF6, 23
- Liquid biopsy, biliary tract cancer, cholangiocarcinoma, ctDNA, cfDNA, review, 441
- Liver metastasis, epithelial-mesenchymal transition (EMT), invasion and migration, *in vivo* metastasis-related models, microRNA (miR), miR-related therapeutic agents, oncogenic signaling pathways, tGF β signaling, tumor- and -metastasis suppressors, review, 453
- Liver, HCC, PP2A, tumor suppressor, ppp2r5d, b56 δ subunit, 2D-DIGE, biomarker, mouse model, hepatocarcinogenesis, fibrinogen, proteomics, 669
- Locked nucleic acids, antisense-oligonucleotides, microRNA delivery, microRNA mimetics, treatment resistance, multiple myeloma, review, 321
- Long noncoding RNA, *iNK4* locus, cell cycle, cyclinB1, CDK inhibitor, 425
- LUM-USP6 fusion gene, aneurysmal bone cyst, chromosome translocation, LUM, USP6, 555
- LUM, aneurysmal bone cyst, chromosome translocation, USP6, LUM-USP6 fusion gene, 555
- Lung cancer, ERCC1, genotype, polymorphism, smoking, Taiwan, 571
- Lung cancer, gigantomol, *Dendrobium draconis*, MYC, proteomics, cell proliferation, 781
- Lung cancer, nitric oxide, microarrays, bioinformatics, transcription factors, epigenetic modifications, 401
- Lung cancer, phosphoproteomics, autophagy, inhibitor, lys05, 369
- Lymph node metastasis, pazopanib, orthotopic tumor, lymphangiogenesis, colorectal cancer, nude mice, 131
- Lymphangiogenesis, pazopanib, orthotopic tumor, lymph node metastasis, colorectal cancer, nude mice, 131
- Lys05, phosphoproteomics, lung cancer, autophagy, inhibitor, 369
- Malignant pleural mesothelioma, biomarkers, proteomic analysis, secretome, proteome, cell lines, 225
- Malignant, CTNNB1, FGFR4, mutation, pilomatricoma, whole-exome sequencing, 795
- Mantle cell lymphoma, BRD4, ChIP-Seq, super-enhancer, drug resistance, 77
- Markers, prostate cancer, quantitative proteomics, SRM, diagnostics, 195
- MDA-MB-231 cells, breast carcinoma, stem cells, stem-like cells, triple-negative breast cancer cells, eph receptors, ephrin ligands, CD44+/CD24- cells, 729
- Mediterranean diet, epigenetic, nutraceuticals, nutrigenomics, cancer, review, 335
- Medulla, proteomics, proteome, high resolution mass spectrometry, nanoLC-MS/MS, tandem mass spectrometry, mouse, brain, cerebral cortex, olfactory bulb, hippocampus, hypothalamus, midbrain, cerebellum, normal mouse brain, normal adult mouse brain, 757
- Mesenchymal subtype, immunoreactive subtype, solid subtype, tILs, tumor stroma, proliferation, 529
- Metabolism, cancer, LDHA, LDHB, GPI, Warburg effect, genes, 469
- Metastasis models, epithelial-mesenchymal transition, microRNA editing, microRNA inhibition and reconstitution of function, migration, invasion and proliferation, therapeutic targets, review, 651
- Metastasis-free survival, renal cell carcinoma, single nucleotide polymorphism, circadian rhythm, overall survival, 827
- Metastasis-related *in vivo* models, antagomirs, intra-hepatic and distant metastasis, functional reconstitution of miRs, *in vivo* metastasis models, miR-mimetics, prognostic correlations, subcutaneous implantation, tail vein injection, therapeutic modalities, therapeutic targets, review, 1
- Metastatic prostate cancer, proteomics, phosphorylation, kinases, 543
- Micro positron emission tomography, biodistribution, bioluminescence, colorectal cancer, pEG-liposome, pharmacokinetics, 61
- Microarrays, nitric oxide, bioinformatics, transcription factors, epigenetic modifications, lung cancer, 401
- MicroRNA (miR), epithelial-mesenchymal transition (EMT), invasion and migration, *in vivo* metastasis-related models, miR-related therapeutic agents, liver metastasis, oncogenic signaling pathways, tGF β signaling, tumor- and -metastasis suppressors, review, 453
- MicroRNA delivery, antisense-oligonucleotides, microRNA mimetics, locked nucleic acids, treatment resistance, multiple myeloma, review, 321
- MicroRNA editing, epithelial-mesenchymal transition, metastasis models, microRNA inhibition and reconstitution of function, migration, invasion and proliferation, therapeutic targets, review, 651
- MicroRNA inhibition and reconstitution of function, epithelial-mesenchymal transition, metastasis models, microRNA editing, migration, invasion and proliferation, therapeutic targets, review, 651

- MicroRNA mimetics, antisense-oligonucleotides, microRNA delivery, locked nucleic acids, treatment resistance, multiple myeloma, review, 321
- MicroRNA, colorectal cancer, cetuximab, panitumumab, chemotherapy, miR-125b, miR-17, let-7c, 605
- MicroRNA, rectal cancer, chemoradiotherapy, prediction, 249
- Microvascular proliferation, glioma, KIT, KDR, artificial intelligence, polymorphism, next-generation sequencing, 715
- Midbrain, proteomics, proteome, high resolution mass spectrometry, nanoLC-MS/MS, tandem mass spectrometry, mouse, brain, cerebral cortex, olfactory bulb, hippocampus, hypothalamus, cerebellum, medulla, normal mouse brain, normal adult mouse brain, 757
- Migration, breast cancer, lincRNA-RP11400K9.4, cell survival, BIRC3, 769
- Migration, epithelial-mesenchymal transition, metastasis models, microRNA editing, microRNA inhibition and reconstitution of function, invasion and proliferation, therapeutic targets, review, 651
- MiR-125b, colorectal cancer, cetuximab, panitumumab, chemotherapy, microRNA, miR-17, let-7c, 605
- MiR-140, colorectal cancer, lipopolysaccharide, cytokines, TRAF6, 23
- MiR-17, colorectal cancer, cetuximab, panitumumab, chemotherapy, microRNA, miR-125b, let-7c, 605
- MiR-mimetics, antagomirs, intra-hepatic and distant metastasis, functional reconstitution of miRs, *in vivo* metastasis models, metastasis-related *in vivo* models, prognostic correlations, subcutaneous implantation, tail vein injection, therapeutic modalities, therapeutic targets, review, 1
- MiR146a, acute lymphoblastic leukemia, case-control study, genotype, polymorphism, Taiwan, 175
- MiR-related therapeutic agents, epithelial-mesenchymal transition (EMT), invasion and migration, *in vivo* metastasis-related models, microRNA (miR), liver metastasis, oncogenic signaling pathways, tGF β signaling, tumor- and -metastasis suppressors, review, 453
- Monitoring markers, circulating tumor DNA, EGFR mutation, non-small cell lung cancer, 417
- Mouse model, HCC, PP2A, tumor suppressor, ppp2r5d, b56 δ subunit, 2D-DIGE, biomarker, hepatocarcinogenesis, fibrinogen, liver, proteomics, 669
- Mouse, proteomics, proteome, high resolution mass spectrometry, nanoLC-MS/MS, tandem mass spectrometry, brain, cerebral cortex, olfactory bulb, hippocampus, hypothalamus, midbrain, cerebellum, medulla, normal mouse brain, normal adult mouse brain, 757
- Multiple myeloma, antisense-oligonucleotides, microRNA delivery, microRNA mimetics, locked nucleic acids, treatment resistance, review, 321
- Mutation, CTNNB1, FGFR4, malignant, pilomatricoma, whole-exome sequencing, 795
- MYC, gigantol, *Dendrobium draconis*, proteomics, cell proliferation, lung cancer, 781
- MYOD1-mutation, adult sclerosing rhabdomyosarcoma, chromosome aberrations, clonal evolution, 563
- NanoLC-MS/MS, proteomics, proteome, high resolution mass spectrometry, tandem mass spectrometry, mouse, brain, cerebral cortex, olfactory bulb, hippocampus, hypothalamus, midbrain, cerebellum, medulla, normal mouse brain, normal adult mouse brain, 757
- NDRG1-PLAG1, chondroid syringoma, PLAG1, fusion genes, TRPS1-PLAG1, Chromosome 8, 237
- Negative regulator, SOX2, transcription factor, breast cancer, cancer stem cell, 359
- Next-generation sequencing, glioma, microvascular proliferation, KIT, KDR, artificial intelligence, polymorphism, 715
- NGS, age, genotype, stromal TIL density, co-mutation, 181
- Nilotinib, CD44, AREG, head and neck squamous cell carcinoma, drug resistance, afatinib, dasatinib, erlotinib, gefitinib, 579
- Nitric oxide, microarrays, bioinformatics, transcription factors, epigenetic modifications, lung cancer, 401
- Non-small cell lung cancer, circulating tumor DNA, EGFR mutation, monitoring markers, 417
- Non-small cell lung cancer, PCTK1/CDK16, biomarker, circulating mRNA, 91
- Normal adult mouse brain, proteomics, proteome, high resolution mass spectrometry, nanoLC-MS/MS, tandem mass spectrometry, mouse, brain, cerebral cortex, olfactory bulb, hippocampus, hypothalamus, midbrain, cerebellum, medulla, normal mouse brain, 757
- Normal fibroblasts, senescence, gluR6, grik2, glutamate receptor, cancer, 707
- Normal mouse brain, proteomics, proteome, high resolution mass spectrometry, nanoLC-MS/MS, tandem mass spectrometry, mouse, brain, cerebral cortex, olfactory bulb, hippocampus, hypothalamus, midbrain, cerebellum, medulla, normal adult mouse brain, 757
- NR2F2-ASI, hemangioma, cytogenetics, karyotype, rNasequencing, chromosome translocation, COL4A5, fusion gene, COL4A5-NR2F2-ASI, 383
- NSCLC, EGFR, co-mutations, concurrent mutations, osimertinib, resistance, 597
- NSCLC, whole-exome sequencing, platinum sensitivity, 587
- Nuclear hTERT, cervical cancer, hTERT protein expression, hTERT localization, cytoplasmic hTERT, hTERT methylation, HPV, 615
- Nude mice, pazopanib, orthotopic tumor, lymph node metastasis, lymphangiogenesis, colorectal cancer, 131
- Nutraceuticals, mediterranean diet, epigenetic, nutrigenomics, cancer, review, 335

- Nutrigenomics, mediterranean diet, epigenetic, nutraceuticals, cancer, review, 335
- Oesophageal squamous cell carcinoma, biomarker, chromobox 2 (*CBX2*), recurrence, 391
- Olfactory bulb, proteomics, proteome, high resolution mass spectrometry, nanoLC-MS/MS, tandem mass spectrometry, mouse, brain, cerebral cortex, hippocampus, hypothalamus, midbrain, cerebellum, medulla, normal mouse brain, normal adult mouse brain, 757
- OLIG1* expression, pediatric T-cell lymphoblastic lymphoma, chromosome translocation t(14;21)(q11;q22), *TRA/TRD* enhancer, *OLIG2* expression, unfavorable prognosis, 41
- OLIG2* expression, pediatric T-cell lymphoblastic lymphoma, chromosome translocation t(14;21)(q11;q22), *TRA/TRD* enhancer, *OLIG1* expression, unfavorable prognosis, 41
- Oncogenic signaling pathways, epithelial-mesenchymal transition (EMT), invasion and migration, *in vivo* metastasis-related models, microRNA (miR), miR-related therapeutic agents, liver metastasis, tGF β signaling, tumor- and -metastasis suppressors, review, 453
- Orthotopic tumor, pazopanib, lymph node metastasis, lymphangiogenesis, colorectal cancer, nude mice, 131
- Osimertinib, EGFR, co-mutations, concurrent mutations, NSCLC, resistance, 597
- Osteoblastoma, *FOS*, fusion gene, *FOS-ANKH*, *FOS-RUNX2*, cytogenetics, RNA sequencing, 161
- Osteosarcoma, cisplatin-resistant, platinum complex, efficacy, 3Pt, PDOX, 217
- Osteosarcoma, pioglitazone, cisplatin, drug resistance, PDOX, pPAR γ , 35
- Overall survival, renal cell carcinoma, single nucleotide polymorphism, circadian rhythm, metastasis-free survival, 827
- P400, breast cancer tumor, TIP60, h4K12ac, heterochromatin, euchromatin, 687
- PanIN, carcinogenesis, PDAC, epigenetics, chromatin accessibility, 695
- Panitumumab, colorectal cancer, cetuximab, chemotherapy, microRNA, miR-125b, miR-17, let-7c, 605
- Papillary thyroid cancer, aCGH, deletion, *SESN2*, senescence, 643
- Patient-derived orthotopic xenograft, PDOX, eribulin, regression, doxorubicin resistance, dedifferentiated liposarcoma, 351
- Pazopanib, orthotopic tumor, lymph node metastasis, lymphangiogenesis, colorectal cancer, nude mice, 131
- PCTK1/CDK16, biomarker, non-small cell lung cancer, circulating mRNA, 91
- PDAC, carcinogenesis, panIN, epigenetics, chromatin accessibility, 695
- PDOX, osteosarcoma, cisplatin-resistant, platinum complex, efficacy, 3Pt, 217
- PDOX, osteosarcoma, pioglitazone, cisplatin, drug resistance, pPAR γ , 35
- PDOX, patient-derived orthotopic xenograft, eribulin, regression, doxorubicin resistance, dedifferentiated liposarcoma, 351
- Pediatric astrocytic tumors, exome analysis, DNA mutations, chromosomal abnormalities, bioinformatics, 117
- Pediatric T-cell lymphoblastic lymphoma, chromosome translocation t(14;21)(q11;q22), *TRA/TRD* enhancer, *OLIG1* expression, *OLIG2* expression, unfavorable prognosis, 41
- Pediatric, benign pediatric soft tissue tumors, soft tissue perineurioma, chromosome translocation, *GABI*, *ABL1*, *GABI-ABL1* fusion gene, der(4)t(4;9)(q31;q34), 499
- PEG-liposome, biodistribution, bioluminescence, colorectal cancer, pharmacokinetics, micro positron emission tomography, 61
- Personalized medicine, targeted sequence panel, whole exome sequence, rectal adenocarcinoma, 291
- Pharmacokinetics, biodistribution, bioluminescence, colorectal cancer, pEG-liposome, micro positron emission tomography, 61
- Phosphoproteomics, lung cancer, autophagy, inhibitor, lys05, 369
- Phosphorylation, metastatic prostate cancer, proteomics, kinases, 543
- Pilomatricoma, CTNNB1, FGFR4, malignant, mutation, whole-exome sequencing, 795
- Pioglitazone, osteosarcoma, cisplatin, drug resistance, PDOX, pPAR γ , 35
- PLAG1*, chondroid syringoma, fusion genes, *NDRG1-PLAG1*, *TRPS1-PLAG1*, Chromosome 8, 237
- Platinum complex, osteosarcoma, cisplatin-resistant, efficacy, 3Pt, PDOX, 217
- Platinum sensitivity, whole-exome sequencing, NSCLC, 587
- Pluripotency, prognosis, breast cancer, cell cycle, 169
- PNCK, hepatocellular carcinoma, prognosis, EGFR, calmodulin, 747
- Polymorphism, acute lymphoblastic leukemia, case-control study, genotype, miR146a, Taiwan, 175
- Polymorphism, ERCC1, genotype, lung cancer, smoking, Taiwan, 571
- Polymorphism, glioma, microvascular proliferation, KIT, KDR, artificial intelligence, next-generation sequencing, 715
- PP2A, HCC, tumor suppressor, ppp2r5d, b56 δ subunit, 2D-DIGE, biomarker, mouse model, hepatocarcinogenesis, fibrinogen, liver, proteomics, 669
- PPAR γ , osteosarcoma, pioglitazone, cisplatin, drug resistance, PDOX, 35

- Ppp2r5d, HCC, PP2A, tumor suppressor, b56δ subunit, 2D-DIGE, biomarker, mouse model, hepatocarcinogenesis, fibrinogen, liver, proteomics, 669
- Prediction, rectal cancer, chemoradiotherapy, microRNA, 249
- Predictive model, proteomic profiling, head and neck squamous cellcarcinoma, recurrence and metastasis, biomarkers, 259
- Prognosis, gastric cancer, *STRA6*, recurrence, biomarker, 509
- Prognosis, hepatocellular carcinoma, PNCK, EGFR, calmodulin, 747
- Prognosis, pluripotency, breast cancer, cell cycle, 169
- Prognostic correlations, antagomirs, intra-hepatic and distant metastasis, functional reconstitution of miRs, *in vivo* metastasis models, miR-mimetics, metastasis-related *in vivo* models, subcutaneous implantation, tail vein injection, therapeutic modalities, therapeutic targets, review, 1
- Proliferation, mesenchymal subtype, immunoreactive subtype, solid subtype, tILs, tumor stroma, 529
- Prostate cancer, cell cycle, recurrence, YWHAZ, biomarker, 209
- Prostate cancer, quantitative proteomics, SRM, diagnostics, markers, 195
- Prostate cancer, vitamin D, vitamin D receptor gene, African American men, single nucleotide polymorphism, 739
- Prostate, genomics, dementia, the Cancer Genome Atlas, carcinoma, 271
- Proteome, malignant pleural mesothelioma, biomarkers, proteomicanalysis, secretome, cell lines, 225
- Proteome, proteomics, high resolution mass spectrometry, nanoLC-MS/MS, tandem mass spectrometry, mouse, brain, cerebral cortex, olfactory bulb, hippocampus, hypothalamus, midbrain, cerebellum, medulla, normal mouse brain, normal adult mouse brain, 757
- Proteomic profiling, head and neck squamous cellcarcinoma, recurrence and metastasis, biomarkers, predictive model, 259
- Proteomicanalysis, malignant pleural mesothelioma, biomarkers, secretome, proteome, cell lines, 225
- Proteomics, gigantol, *Dendrobium draconis*, MYC, cell proliferation, lung cancer, 781
- Proteomics, HCC, PP2A, tumor suppressor, ppp2r5d, b56δ subunit, 2D-DIGE, biomarker, mouse model, hepatocarcinogenesis, fibrinogen, liver, 669
- Proteomics, metastatic prostate cancer, phosphorylation, kinases, 543
- Proteomics, proteome, high resolution mass spectrometry, nanoLC-MS/MS, tandem mass spectrometry, mouse, brain, cerebral cortex, olfactory bulb, hippocampus, hypothalamus, midbrain, cerebellum, medulla, normal mouse brain, normal adult mouse brain, 757
- PTEN, epithelial ovarian cancer, tumor marker, TRPV1, 309
- Quantitative proteomics, prostate cancer, SRM, diagnostics, markers, 195
- Rectal cancer, chemoradiotherapy, microRNA, prediction, 249
- Rectal adenocarcinoma, targeted sequence panel, whole exome sequence, personalized medicine, 291
- Recurrence and metastasis, proteomic profiling, head and neck squamous cellcarcinoma, biomarkers, predictive model, 259
- Recurrence, biomarker, chromobox 2 (*CBX2*), oesophageal squamous cell carcinoma, 391
- Recurrence, brain, glioblastoma, evolutionary pattern, targeted sequencing, 803
- Recurrence, cell cycle, prostate cancer, YWHAZ, biomarker, 209
- Recurrence, gastric cancer, *STRA6*, prognosis, biomarker, 509
- Regression, patient-derived orthotopic xenograft, PDOX, eribulin, doxorubicin resistance, dedifferentiated liposarcoma, 351
- Renal cell carcinoma, single nucleotide polymorphism, circadian rhythm, overall survival, metastasis-free survival, 827
- Replication stress, CMG helicase uncoupling, g-quadruplex, i-motif, 101
- Resistance, EGFR, co-mutations, concurrent mutations, NSCLC, osimertinib, 597
- Review, antagomirs, intra-hepatic and distant metastasis, functional reconstitution of miRs, *in vivo* metastasis models, miR-mimetics, metastasis-related *in vivo* models, prognostic correlations, subcutaneous implantation, tail vein injection, therapeutic modalities, therapeutic targets, 1
- Review, antisense-oligonucleotides, microRNA delivery, microRNA mimetics, locked nucleic acids, treatment resistance, multiple myeloma, 321
- Review, epithelial-mesenchymal transition (EMT), invasion and migration, *in vivo* metastasis-related models, microRNA (miR), miR-related therapeutic agents, liver metastasis, oncogenic signaling pathways, tGFβ signaling, tumor- and -metastasis suppressors, 453
- Review, epithelial-mesenchymal transition, metastasis models, microRNA editing, microRNA inhibition and reconstitution of function, migration, invasion and proliferation, therapeutic targets, 651
- Review, liquid biopsy, biliary tract cancer, cholangiocarcinoma, ctDNA, cfDNA, 441
- Review, mediterranean diet, epigenetic, nutraceuticals, nutrigenomics, cancer, 335
- RNA sequencing, osteoblastoma, *FOS*, fusion gene, *FOS-ANKH*, *FOS-RUNX2*, cytogenetics, 161
- RNAsequencing, hemangioma, cytogenetics, karyotype, chromosome translocation, *COL4A5*, *NR2F2-AS1*, fusion gene, *COL4A5-NR2F2-AS1*, 383

- ROS, ERK, STAT3, apoptosis, cell cycle, ALL, 517
- Secretome, malignant pleural mesothelioma, biomarkers, proteomic analysis, proteome, cell lines, 225
- Senescence, normal fibroblasts, *gluR6*, *grik2*, glutamate receptor, cancer, 707
- Senescence, papillary thyroid cancer, aCGH, deletion, *SESN2*, 643
- SESN2*, papillary thyroid cancer, aCGH, deletion, senescence, 643
- Single nucleotide polymorphism, prostate cancer, vitamin D, vitamin D receptor gene, African American men, 739
- Single nucleotide polymorphism, renal cell carcinoma, circadian rhythm, overall survival, metastasis-free survival, 827
- Smoking, *ERCC1*, genotype, lung cancer, polymorphism, Taiwan, 571
- Soft tissue perineurioma, benign pediatric soft tissue tumors, pediatric, chromosome translocation, *GABI*, *ABL1*, *GABI-ABL1* fusion gene, der(4)t(4;9)(q31;q34), 499
- Solid subtype, mesenchymal subtype, immunoreactive subtype, tILs, tumor stroma, proliferation, 529
- SOX2*, negative regulator, transcription factor, breast cancer, cancer stem cell, 359
- Squamous cell carcinoma, vulvar cancer, vulvar neoplasms, *Lichen sclerosus*, vulvar *Lichen sclerosus*, differentiated vulvar intraepithelial neoplasia, clonal evolution, 151
- SRM, prostate cancer, quantitative proteomics, diagnostics, markers, 195
- STAT3, ERK, apoptosis, cell cycle, ROS, ALL, 517
- Stem cells, breast carcinoma, stem-like cells, triple-negative breast cancer cells, eph receptors, ephrin ligands, CD44+/CD24- cells, MDA-MB-231 cells, 729
- Stem-like cells, breast carcinoma, stem cells, triple-negative breast cancer cells, eph receptors, ephrin ligands, CD44+/CD24- cells, MDA-MB-231 cells, 729
- STRA6*, gastric cancer, recurrence, prognosis, biomarker, 509
- Stromal TIL density, age, genotype, co-mutation, NGS, 181
- Subcutaneous implantation, antagomirs, intra-hepatic and distant metastasis, functional reconstitution of miRs, *in vivo* metastasis models, miR-mimetics, metastasis-related *in vivo* models, prognostic correlations, tail vein injection, therapeutic modalities, therapeutic targets, review, 1
- Super-enhancer, mantle cell lymphoma, *BRD4*, chIP-Seq, drug resistance, 77
- Tail vein injection, antagomirs, intra-hepatic and distant metastasis, functional reconstitution of miRs, *in vivo* metastasis models, miR-mimetics, metastasis-related *in vivo* models, prognostic correlations, subcutaneous implantation, therapeutic modalities, therapeutic targets, review, 1
- Taiwan, acute lymphoblastic leukemia, case-control study, genotype, miR146a, polymorphism, 175
- Taiwan, *ERCC1*, genotype, lung cancer, polymorphism, smoking, 571
- Tandem mass spectrometry, proteomics, proteome, high resolution mass spectrometry, nanoLC-MS/MS, mouse, brain, cerebral cortex, olfactory bulb, hippocampus, hypothalamus, midbrain, cerebellum, medulla, normal mouse brain, normal adult mouse brain, 757
- Targeted sequence panel, whole exome sequence, rectal adenocarcinoma, personalized medicine, 291
- Targeted sequencing, brain, glioblastoma, recurrence, evolutionary pattern, 803
- Targeted sequencing, uterus, cervix, usual-type endocervical adenocarcinoma, gastric-type mucinous carcinoma, immunohistochemistry, 627
- TERT*, leucocyte telomeres, *TRF1*, *TNKS2*, laryngeal carcinoma, gene polymorphisms, 431
- TGF β signaling, epithelial-mesenchymal transition (EMT), invasion and migration, *in vivo* metastasis-related models, microRNA (miR), miR-related therapeutic agents, liver metastasis, oncogenic signaling pathways, tumor- and -metastasis suppressors, review, 453
- The Cancer Genome Atlas, genomics, dementia, prostate, carcinoma, 271
- Therapeutic modalities, antagomirs, intra-hepatic and distant metastasis, functional reconstitution of miRs, *in vivo* metastasis models, miR-mimetics, metastasis-related *in vivo* models, prognostic correlations, subcutaneous implantation, tail vein injection, therapeutic targets, review, 1
- Therapeutic targets, antagomirs, intra-hepatic and distant metastasis, functional reconstitution of miRs, *in vivo* metastasis models, miR-mimetics, metastasis-related *in vivo* models, prognostic correlations, subcutaneous implantation, tail vein injection, therapeutic modalities, review, 1
- Therapeutic targets, epithelial-mesenchymal transition, metastasis models, microRNA editing, microRNA inhibition and reconstitution of function, migration, invasion and proliferation, review, 651
- TILs, mesenchymal subtype, immunoreactive subtype, solid subtype, tumor stroma, proliferation, 529
- TIP60*, breast cancer tumor, h4K12ac, P400, heterochromatin, euchromatin, 687
- TNKS2*, leucocyte telomeres, *TERT*, *TRF1*, laryngeal carcinoma, gene polymorphisms, 431
- TRA/TRD* enhancer, pediatric T-cell lymphoblastic lymphoma, chromosome translocation t(14;21)(q11;q22), *OLIG1* expression, *OLIG2* expression, unfavorable prognosis, 41
- TRAF6*, colorectal cancer, lipopolysaccharide, miR-140, cytokines, 23
- Transcription factor, *SOX2*, negative regulator, breast cancer, cancer stem cell, 359

- Transcription factors, nitric oxide, microarrays, bioinformatics, epigenetic modifications, lung cancer, 401
- Treatment resistance, antisense-oligonucleotides, microRNA delivery, microRNA mimetics, locked nucleic acids, multiple myeloma, review, 321
- TRF1*, leucocyte telomeres, *TERT*, *TNKS2*, laryngeal carcinoma, gene polymorphisms, 431
- Triple-negative breast cancer cells, breast carcinoma, stem cells, stem-like cells, eph receptors, ephrin ligands, CD44+/CD24- cells, MDA-MB-231 cells, 729
- TRPS1-PLAG1*, chondroid syringoma, *PLAG1*, fusion genes, *NDRG1-PLAG1*, Chromosome 8, 237
- TRPV1, epithelial ovarian cancer, tumor marker, PTEN, 309
- Tumor marker, epithelial ovarian cancer, TRPV1, PTEN, 309
- Tumor stroma, mesenchymal subtype, immunoreactive subtype, solid subtype, tILs, proliferation, 529
- Tumor suppressor, HCC, PP2A, ppp2r5d, b56δ subunit, 2D-DIGE, biomarker, mouse model, hepatocarcinogenesis, fibrinogen, liver, proteomics, 669
- Tumor- and -metastasis suppressors, epithelial-mesenchymal transition (EMT), invasion and migration, *in vivo* metastasis-related models, microRNA (miR), miR-related therapeutic agents, liver metastasis, oncogenic signaling pathways, tGFβ signaling, review, 453
- Unfavorable prognosis, pediatric T-cell lymphoblastic lymphoma, chromosome translocation t(14;21)(q11;q22), *TRA/TRD* enhancer, *OLIG1* expression, *OLIG2* expression, 41
- USP6, aneurysmal bone cyst, chromosome translocation, LUM, LUM-USP6 fusion gene, 555
- Usual-type endocervical adenocarcinoma, uterus, cervix, gastric-type mucinous carcinoma, immunohistochemistry, targeted sequencing, 627
- Uterus, cervix, atypical mesonephric hyperplasia, Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) mutation, Chromosome 1q gain, 813
- Uterus, cervix, usual-type endocervical adenocarcinoma, gastric-type mucinous carcinoma, immunohistochemistry, targeted sequencing, 627
- Vitamin D receptor gene, prostate cancer, vitamin D, African American men, single nucleotide polymorphism, 739
- Vitamin D, prostate cancer, vitamin D receptor gene, African American men, single nucleotide polymorphism, 739
- Vulvar cancer, vulvar neoplasms, squamous cell carcinoma, *Lichen sclerosus*, vulvar *Lichen sclerosus*, differentiated vulvar intraepithelial neoplasia, clonal evolution, 151
- Vulvar *Lichen sclerosus*, vulvar cancer, vulvar neoplasms, squamous cell carcinoma, *Lichen sclerosus*, differentiated vulvar intraepithelial neoplasia, clonal evolution, 151
- Vulvar neoplasms, vulvar cancer, squamous cell carcinoma, *Lichen sclerosus*, vulvar *Lichen sclerosus*, differentiated vulvar intraepithelial neoplasia, clonal evolution, 151
- Warburg effect, cancer, metabolism, LDHA, LDHB, GPI, genes, 469
- Whole exome sequence, targeted sequence panel, rectal adenocarcinoma, personalized medicine, 291
- Whole-exome sequencing, CTNNB1, FGFR4, malignant, mutation, pilomatricoma, 795
- Whole-exome sequencing, platinum sensitivity, NSCLC, 587
- YWHAZ, cell cycle, prostate cancer, recurrence, biomarker, 209

Authors Index

(Figures refer to page numbers)

- Abdelhamid MAS, 101
 Acosta J, 615
 Addeo A, 597
 Aderhold C, 579
 Alifano M, 587
 Amorim CKN, 643
 Amparo C, 101
 Anagnostopoulos AK, 757
 Andersen K, 41, 161, 237, 383, 499, 555
 Anjo SI, 259
 Apprey V, 739
 Araki Y, 217
 Aravantinos G, 181
 Arnogiannaki N, 181
 Athanasiadis I, 181
 Athwal RS, 707
 Auslaender S, 453
 Ausländer S, 651
 Baba H, 391
 Badisa R, 469
 Bae GE, 627, 795
 Bao B-Y, 209, 827
 Barbosa Melo J, 259
 Barone M, 301
 Barroso L, 259
 Bau D-T, 61, 175, 571
 Bedell V, 101
 Beiske K, 41
 Bellazzi R, 117
 Berindan-Neagoe I, 249
 Bernard-Gallon D, 687
 Beyene DA, 739
 Bignon Y-J, 687
 Birk R, 579
 Birzele F, 1
 Bjerkehagen B, 161, 563
 Bobos M, 181, 277
 Boisnier T, 687
 Bompolaki I, 181
 Bonotti A, 225
 Bouvet M, 35, 131
 Brandi G, 441
 Brinkmann U, 1, 453, 651
 Bruha J, 605
 Bruno E, 301
 Buitrago L, 615
 Bulten J, 151
 Cai S, 49
 Canny E, 587
 Casamassima P, 301
 Cassim S, 469
 Castro J, 615
 Cechakova L, 369
 Chang JW-C, 91
 Chang W-S, 61, 175, 571
 Chanvorachote P, 401, 781
 Chao K-SC, 291
 Chatzidakis I, 277
 Chatzopoulos K, 181
 Chay DB, 309
 Chen C-C, 175
 Chen JC-H, 61
 Chen L-C, 209, 827
 Chen L-H, 571
 Chen T-W, 291
 Chen WT-L, 291
 Cheng Z, 23
 Chevallier M, 597
 Chiang S-F, 291
 Chien Y-C, 61
 Chin Y-T, 175
 Chinen Y, 77
 Chiou C-C, 91, 417
 Chiu K-L, 571
 Cho H, 309
 Cho Y-C, 543
 Cho YA, 747
 Choi S, 747
 Chou Y-H, 61
 Chrisafi S, 277, 529
 Chun SY, 195
 Chung J-Y, 309
 Ciccone R, 117
 Ciregia F, 225
 Clark J, 101
 Colangelo D, 301
 Comincini S, 117
 Copeland RL, 739
 Cristaudo A, 225
 Cui Y, 49
 D'Antongiovanni V, 225
 Da Silva Maués JH, 643
 Damotte D, 587
 Daniele A, 301, 335
 Daremipouran MR, 739
 Dass SS, 715
 De Almeida DCN, 643
 De Hullu JA, 151
 De Oliveira EHC, 643
 De Souza MPC, 643
 De Vos R, 669
 Derua R, 669
 Digennaro M, 301
 Dima S, 587
 Divella R, 301, 335
 Do S-I, 813
 Doki Y, 141
 Dosoudil M, 249
 Dry SM, 217
 Efstratiou I, 529
 Eguchi H, 141
 Eijkelenboom A, 151
 Espenel S, 615
 Esteves L, 259
 Fabrik I, 369
 Fallahi P, 225
 Farkasova M, 249
 Fernández-Rojas MA, 769
 Ferreira GB, 669
 Fiala L, 249
 Fiala O, 605
 Finek J, 605
 Florou A, 277
 Foddiss R, 225
 Fountzilias G, 181, 277, 529
 Friedlaender A, 597
 Fujii A, 141
 Fujii T, 391
 Fujiwara H, 695
 Gabriele F, 117
 Gallagher L, 715
 Gamboa O, 615
 Gao Y, 543
 Garland SM, 615
 Gedvilaite G, 431
 Giannaccini G, 225
 Giannoulidou E, 181, 277
 Giannouzakos VG, 277
 Giusti L, 225
 Gogas H, 181
 Gong C-L, 175, 571
 González-Prieto C, 615
 Gorunova L, 41, 161, 237, 383, 499, 555, 563
 Greco V, 225
 Grigoriou M, 587
 Grollich T, 249
 Ha SY, 747
 Ha Y-S, 195, 543
 Hamada J-I, 359
 Han GH, 309
 Han Q, 131
 Hatakeyama S, 359
 Hattori N, 509
 Hayakawa Y, 695
 Hayashi K, 35, 217, 351
 Hayashi M, 509
 Hehir-Kwa JY, 151
 Heim S, 41, 161, 237, 383, 499, 555, 563
 Hendriks KM, 151
 Higuchi T, 35, 217, 351
 Hirata Y, 695
 Hirose T, 359
 Hoffman RM, 23, 35, 131, 217, 351
 Holth A, 41
 Hosek P, 605
 Hsia T-C, 571
 Hsiao Y-C, 571
 Hsieh J-J, 91
 Hsu P-C, 175
 Hsu Y-N, 175
 Hsueh Y-M, 827
 Hu Q, 141
 Huang C-Y, 209, 827
 Huang KC-Y, 291
 Huang S-P, 209, 827
 Huang T-L, 175
 Huang Y, 23
 Huber L, 579
 Hwang J-J, 61
 Idrissou M, 687
 Igarashi K, 35, 217, 351
 Iizasa H, 359
 Ijichi H, 695
 Inaba T, 77
 Janssens V, 669
 Jasek-Gajda E, 517
 Jasińska M, 517
 Ji J, 49
 Jiang WG, 49, 169
 Jimenez B, 729
 Johannsdottir IMR, 41
 Jung H, 627
 Jurkowska H, 517
 Kakiuchi M, 695
 Kala Z, 249
 Kamping EJ, 151
 Kanaan YM, 739
 Kanai A, 77
 Kanda M, 391, 509
 Kandpal RP, 707, 729
 Kansy B, 579
 Kassim OO, 739
 Kato H, 695
 Kawaguchi K, 217, 351
 Kawaji Y, 77
 Ke T-W, 291
 Khorashad JS, 715
 Khoufah FZH, 687
 Kim H-S, 627, 803, 813
 Kim H, 813
 Kim HM, 627
 Kim J-H, 309

- Kimura H, 35, 217, 351
 Kiss I, 249
 Kitagawa A, 141
 Kiyuna T, 351
 Klepetko W, 587
 Klimentova J, 369
 Ko H-W, 417
 Kobayashi Y, 141
 Kodera Y, 391, 509
 Koike K, 695
 Koike M, 509
 Koliou G-A, 181, 277, 529
 Korovesi AG, 757
 Kostolomov I, 161
 Kotake Y, 425
 Kotoula V, 181, 277, 529
 Kouyama Y, 141
 Kramer B, 579
 Kucera R, 605
 Kudo Y, 695
 Kuiper RP, 151
 Kuo C-C, 175
 Kuramitsu S, 141
 Kuramitsu Y, 359
 Kuroda J, 77
 Kuroda Y, 141
 Kuwahara-Ota S, 77
 Kwon OK, 195
 Kwon TG, 195, 543
 Lacerenza S, 225
 Lagunas VM, 769
 Lakis S, 529
 Lambrecht C, 669
 Lammert A, 579
 Lang S, 579
 Laszlo V, 587
 Lee C-H, 209
 Lee E-J, 803, 813
 Lee JN, 195, 543
 Lee JW, 803
 Lee S, 195, 543
 Lehrer S, 271
 Li C-H, 571
 Li Y, 217
 Liang S, 359
 Libbrecht L, 669
 Limbäck-Stanic C, 715
 Lin C, 23
 Lin VC, 209
 Lin W-H, 209
 Lis GJ, 517
 Liska V, 605
 Litwin JA, 517
 Liu C-Y, 417
 Liu C, 49
 Liutkeviciene R, 431
 Liutkevicius V, 431
 Lobmaier I, 161, 237, 383, 499, 555
 Losuwannarak N, 781
 Lu T-L, 209, 827
 Lucacchini A, 225
 Lucero M, 729
 Ludwig S, 579
 Lund-Iversen M, 161, 237, 383, 499, 555
 Luo J-D, 91, 417
 Lupo A, 587
 Maceckova D, 605
 Machackova T, 249
 Mack N, 469
 Macmahon S, 715
 Maegawa-Matsui S, 77
 Maeng L-S, 803
 Magné N, 615
 Maiuthed A, 401
 Manadas B, 259
 Manai F, 117
 Marques Carreira I, 259
 Marques F, 259
 Martella M, 101
 Martin TA, 169
 Martinelli C, 117
 Massuger LFAG, 151
 Masuda T, 141
 Mathieu C, 669
 Matsumura-Kimoto Y, 77
 Mayorga D, 615
 Mazzio E, 469
 Mazzoni MR, 225
 Mejía JC, 615
 Melendez-Zajgla J, 769
 Micci F, 237, 383, 499, 555, 563
 Mimori K, 141
 Minoia C, 301
 Misra S, 217
 Miwa S, 35, 217, 351
 Miyake K, 351
 Mizuno Y, 77
 Mokbel K, 169
 Molano M, 615
 Morales N, 615
 Moreira-Nunes CA, 643
 Moreno-Acosta P, 615
 Mori M, 141
 Morinaga S, 217
 Morishita K, 77
 Moroni I, 117
 Motoyama S, 391
 Murata-Collins JL, 101
 Murray GL, 615
 Na A-Y, 195
 Na K, 813
 Naab T, 739
 Nakagawa H, 695
 Nakahata S, 77
 Nakamura S, 391, 509
 Nakano M, 77
 Nakatsuka T, 695
 Nakayama G, 509
 Nam S, 309
 Nastase A, 587
 Nelson SD, 217
 Nicolaou I, 181
 Nikolaidi A, 181
 Nishino H, 35
 Noda M, 141
 Nomoto S, 391
 Nopora A, 321
 Novara F, 117
 Odani A, 217
 Oikonomopoulos G, 181
 Oliverio A, 301
 Omae K, 509
 Omella JD, 669
 Ondrej M, 369
 Orakzai MAW, 169
 Otsuka M, 695
 Overbergh L, 669
 Panagopoulos I, 41, 161, 237, 383, 499, 555, 563
 Papadopoulou K, 181, 277
 Papakostas P, 181
 Papanikolaou A, 529
 Papavasileiou C, 277
 Paradiso A, 335
 Paradiso AV, 301
 Parcq PD, 715
 Park C-K, 747
 Park S, 747
 Pasanisi P, 301
 Patane M, 117
 Patera R, 117
 Patruno M, 301
 Pectasides D, 181, 277
 Pectasides E, 277
 Pei J-S, 175
 Penault-Llorca F, 687
 Pentheroudakis G, 181
 Pichiorri F, 101
 Pieroni L, 225
 Pierros V, 757
 Pilato B, 301
 Pitule P, 605
 Popescu I, 587
 Pouwer A-FW, 151
 Pouyssegur J, 469
 Prakhongcheep O, 401
 Prochazka V, 249
 Rheinsteinst PH, 271
 Ribeiro IP, 259
 Ricci AD, 441
 Rizzo A, 441
 Romero-Rojas A, 615
 Rotter N, 579
 Roytrakul S, 781
 Saloustros E, 181
 Sanchez A, 687
 Sandoval J, 729
 Sano M, 695
 Santo Sagica FDE, 643
 Sato K, 141
 Sato R, 77
 Sato Y, 391
 Sauta E, 117
 Savino E, 301, 335
 Sawaki K, 391, 509
 Schmid D, 1
 Sefr R, 249
 Senaati S, 729
 Shen T-C, 571
 Shih C-L, 91
 Shimizu D, 141, 391, 509
 Shinkai Y, 695
 Singh SR, 23, 35, 131, 217, 351
 Skrovina M, 249
 Slaby O, 249
 Smith SS, 101
 Soliman KFA, 469
 Sorejs O, 605
 Stravopodis DJ, 757
 Sugisawa N, 35
 Sun Y, 131
 Sun Z, 49
 Svoboda M, 249
 Tachibana M, 695
 Taffjord S, 499
 Takahashi H, 359
 Takahashi J, 141
 Takimoto-Shimomura T, 77
 Tan Y, 131
 Tanaka C, 509
 Tanaka Y, 695
 Taniguchi Y, 217
 Taniwaki M, 77
 Tashiro K, 77
 Tashiro Y, 35
 Tateishi K, 695
 Tavolari S, 441
 Tayeh S, 169
 Thind J, 729
 Thompson L, 715
 Tichy A, 369
 Tobo T, 141
 Tommasi S, 301
 Topolcan O, 605
 Trachtova K, 249
 Tsai C-W, 61, 175, 571
 Tsangaris GTH, 757

Tsantoulis P, 597	Vycital O, 605	Woo HY, 813	Yoshiyama H, 359
Tsuchiya H, 35, 217, 351	Waelkens E, 669	Yamada S, 509	Yu C-C, 209
Tsukamoto T, 77	Wakiyama H, 141	Yamamoto J, 35	Yu C-J, 91
Tsuruda T, 425	Waller ZAE, 101	Yamamoto K, 695	Yu J, 151
Tsuruda Y, 141	Wang C-L, 91, 417	Yamamoto N, 35, 217, 351	Zagouri F, 181
Tufaro A, 301	Wang C-W, 91	Yang C-T, 417	Zaman N, 715
Ueda S, 391	Wang Q, 23	Yang S, 23	Zdravlevic M, 469
Uloza V, 431	Wang R, 359	Ye J, 23, 131	Zebekakis P, 529
Vaiciulis P, 431	Wang W-H, 61	Ye L, 49	Zhao M, 131
Vallard A, 615	Wang Y-C, 175, 571	Yeo M-K, 795	Zhawar VK, 707
Van Den Einden LCG, 151	Wang Z-H, 571	Yonezawa H, 217	Zheng W, 23
Van Der Linden M, 151	Warner EF, 101	Yoon N, 803, 813	Zhu G, 23, 131
Van Tilborg AAG, 151	Wazir U, 169	Yoon WS, 803	
Vilkeviciute A, 431	Weidle UH, 1, 321, 453, 651	Yoshikawa Y, 141	

Instructions for Authors 2021

General Policy. CANCER GENOMICS & PROTEOMICS (CGP) welcomes the submission of high quality original articles and reviews on all aspects of the application of genomic and proteomic technologies to experimental and clinical cancer research. The journal's scientific spectrum includes: (a) molecular causes of carcinogenesis, cancer progression and metastasis; (b) structural and functional aspects of genes in the cancer cell; (c) advances in genomic and proteomic technologies applicable to cancer research; (d) rational anticancer drug design and drug development. Each article should include a concrete conclusion constituting of a "new piece of knowledge" backed up by scientific evidence. CGP will also accept abstracts and proceedings of scientific meetings for publication, following consideration and approval by the Editorial Board.

The principal aim of CGP is to provide for the prompt online publication of original works of high quality, generally within 1-2 months of final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works that are not under consideration for publication by another journal (print or online), and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to CGP will be subject to peer-review by two members of the Editorial Board and by one suitable outside referee. All manuscripts submitted to CGP are urgently treated with absolute confidence, with access restricted to the Editor-in-Chief, the Managing Editor, the journal's secretary, the reviewers and the printers. The Editors reserve the right to improve manuscripts in terms of grammar and style.

The Editors and Publishers of CGP accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

Open Access Policy. CGP appears bimonthly as an online-only open access journal through the Stanford University HighWire Press. Upon acceptance, Authors will be asked to pay an online publication fee of USD 900.00 (effective January 1, 2021) for articles up to 8 online pages (including figures and tables). Each additional excess page will be charged USD 60.00. Color will not be charged. Authors from developing countries may apply for a 25% discount after the acceptance of their paper. CGP online will keep the volume and issue numbers, as well as page numbering.

Copyright. Authors retain copyright. The unrestricted non-commercial use, distribution and reproduction in any medium of CGP articles for academic reasons is allowed, provided that the original work is properly cited. The Authors grant the permanent right to the publisher to use any articles published in this journal without any restriction, including academic advertising purposes. PDF, XML and html files of all articles published in CGP are the property of the publisher.

Format. Two types of papers may be submitted: (i) full papers containing completed original work, and (ii) review articles concerning fields of recognizable progress. Papers should contain all the essential data in order to make the presentation clear. Papers should be written in clear, concise English. Spelling should follow that of the "Oxford English Dictionary".

Manuscripts. All manuscripts should be divided into the following sections: (a) *First page* including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) *Abstract* not exceeding 150 words, organized according to the following headings: Background - Materials and Methods or Patients and Methods - Results - Conclusion; (c) *Introduction*; (d) *Materials and Methods* or *Patients and Methods*; (e) *Results*; (f) *Discussion*; (g) *Conflicts of Interest*; (h) *Authors' contributions*; (i) *Acknowledgements*; (j) *References*. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's preference. Review articles should not exceed 35 pages (approximately 250 words per double-spaced page) including all tables, figures and references.

Figures. All figures should appear at the end of the submitted document file. Once a manuscript is accepted all figures and graphs should be submitted separately in either jpg, tiff or pdf format and at a minimum resolution of 300 dpi. Graphs must be submitted as pictures made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated.

Tables. All tables should appear at the end of the submitted document file. Once a manuscript is accepted, each table should be submitted separately, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

References. Authors must assume responsibility for the accuracy of the references used. Citations for the reference sections of submitted works should follow the form below and must be numbered consecutively. In the text, references should be cited by number in parenthesis. Examples: 1 Kenyon J, Liu W and Dalglish A: Report of objective clinical responses of cancer patients to pharmaceutical-grade synthetic cannabidiol. *Anticancer Res* 38(10): 5831-5835, 2018. PMID: 30275207. DOI: 10.21873/anticancer.12924. (PMIDs and DOIs only if applicable). 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones*. O' Malley BW, Chamnes GC (eds.).

New York, Plenum Publ Corp., pp 113-136, 1973. 3 Global Health Estimates 2015: Disease Burden by Cause, Age, Sex, by Country and by Region, 2000-2015. Geneva, World Health Organisation, 2016. Available at http://www.who.int/healthinfo/global_burden_disease/estimates/en/index2.html. Last accessed on 3rd April 2018. (The web address should link directly to the cited information and not to a generic webpage).

Nomenclature and Abbreviations. Nomenclature should follow that given in “Chemical Abstracts”, “Index Medicus”, “Merck Index”, “IUPAC-IUB”, “Bergey’s Manual of Determinative Bacteriology”, The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (<http://www.gene.ucl.ac.uk/>). Approved mouse nomenclature may be obtained from <http://www.informatics.jax.org/>. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text. For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by ‘ISRCTN’). Please note that there is no space between the prefix ‘ISRCTN’ and the number. Example: ISRCTN47956475. For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by ‘NCT’). Please note that there is no space between the prefix ‘NCT’ and the number. Example: NCT00001789.

Ethical Policies and Standards. CGP agrees with and follows the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals” established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the “Minimum Information About Microarray Experiments (MIAME) standard”. Specific guidelines are provided at the “Microarray Gene Expression Data Society” (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions for Authors regarding the format of your manuscript and references. Manuscripts must be submitted only through our online submission system at: <http://www.iar-submissions.com/login.html> In case a submission is incomplete, the corresponding Author will be notified accordingly. Questions regarding difficulties in using the online submission system should be addressed to: email: journals@iia-anticancer.org

Editorial Office: International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki 19014, Greece. Tel / Fax: +30-22950-53389.

Editorial Office in U.S.A.: Anticancer Research USA, Inc., 111 Bay Avenue, Highlands, NJ 07732, USA.

E-mails: Editorial Office: journals@iia-anticancer.org. Managing Editor: editor@iia-anticancer.org.

Galley Proofs. Galley proofs will be sent by e-mail to the corresponding Author. Corrections of galley proofs should be limited to typographical errors. Galley proofs should be returned corrected to the Editorial Office by email within two days.

Specific information and additional instructions for Authors

1. Cancer Genomics & Proteomics (CGP) will consider the publication of conference proceedings and/or abstracts provided that the material submitted fulfils the quality requirements and instructions of the journal, following the regular review process by two suitable referees.
2. An acknowledgement of receipt, including the article number, title and date of receipt is sent to the corresponding author of each manuscript upon receipt. If this receipt is not received within 20 days from submission, the author should call or write to the Editorial Office to ensure that the manuscript (or the receipt) was not lost in the mail.
3. Each manuscript submitted to CGP is sent for peer-review in confidence to two suitable referees with the request to return the manuscript with their comments to the Editorial Office within 12 days from receipt. If reviewers need a longer time or wish to send the manuscript to another expert, the manuscript may be returned to the Editorial Office with a delay. All manuscripts submitted to CGP, are treated in confidence, without access to any person other than the Managing Editor, the journal’s secretary, the reviewers and the printers.

4. All accepted manuscripts are carefully corrected in style and language, if necessary, to make presentation clear. (There is no fee for this service). Every effort is made (a) to maintain the personal style of the author's writing and (b) to avoid change of meaning. Authors will be requested to examine carefully manuscripts which have undergone language correction at the pre-proof or proof stage.
5. Authors should pay attention to the following points when writing an article for CGP:
 - The Instructions to Authors must be followed in every detail.
 - The presentation of the experimental methods should be clear and complete in every detail facilitating reproducibility by other scientists.
 - The presentation of results should be simple and straightforward in style. Results and discussion should not be combined into one section, unless the paper is short.
 - Results given in figures should not be repeated in tables.
 - Figures (graphs or photographs) should be prepared at a width of 8 or 17 cm with legible numbers and lettering.
 - Photographs should be clear with high contrast, presenting the actual observation described in the legend and in the text. Each legend should provide a complete description, being self-explanatory, including technique of preparation, information about the specimen and magnification.
 - Statistical analysis should be elaborated wherever it is necessary. Simplification of presentation by giving only numerical or % values should be avoided.
 - Fidelity of the techniques and reproducibility of the results, should be points of particular importance in the discussion section. Authors are advised to check the correctness of their methods and results carefully before writing an article. Probable or dubious explanations should be avoided.
 - Authors should not cite results submitted for publication in the reference section. Such results may be described briefly in the text with a note in parenthesis (submitted for publication by... authors, year).
 - References. Each article should address, list and discuss the entire spectrum of current publications relevant to its field.
 - By following these instructions, Authors will facilitate a more rapid review and processing of their manuscripts and will provide the readers with concise and useful papers.
6. Following review and acceptance, a manuscript is examined in language and style, and galley proofs are rapidly prepared. Second proofs are not sent unless required.
7. Authors should correct their galley proofs very carefully and preferably twice. An additional correction by a colleague always proves to be useful. Particular attention should be paid to chemical formulas, mathematical equations, symbols, medical nomenclature etc. Any system of correction marks can be used in a clear manner, preferably with a red pen. Additions or clarifications are allowed provided that they improve the presentation but do not bring new results (no fee).
8. Articles submitted to CGP may be rejected without review if:
 - they do not fall within the journal's policy.
 - they do not follow the instructions for authors.
 - language is unclear.
 - results are not sufficient to support a final conclusion.
 - results are not objectively based on valid experiments.
 - they repeat results already published by the same or other authors before the submission to CGP.
 - plagiarism is detected by plagiarism screening services.
 (Rejection rate (2020): 72%).
9. Authors who wish to prepare a review should contact the Managing Editor of the journal in order to get confirmation of interest in the particular topic of the review and to allow programming of space availability. The expression of interest by the Managing Editor does not necessarily imply acceptance of the review by the journal.
10. Authors may inquire information about the status of their manuscript(s) by calling the Editorial Office at +30-22950-53389, Monday to Friday 9.00-16.00 (Athens time), or by sending an e-mail to journals@iia-anticancer.org.
11. Authors who wish to edit a special issue on a particular topic should contact the Managing Editor.

(This text is a combination of advice and suggestions contributed by Editors, Authors, Readers and the Managing Editor of CGP).

Copyright© 2020-21 International Institute of Anticancer Research (G.J. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.

CANCER GENOMICS & PROTEOMICS supports (a) the aims and the research projects of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (IIAR, Kapandriti, Attiki, Greece) and (b) the organization of the International Conferences of Anticancer Research.

CANCER GENOMICS & PROTEOMICS appears online with Stanford University HighWire Press.

For more information about CANCER GENOMICS & PROTEOMICS, IIAR and the Conferences please visit our websites: www.iiar-anticancer.org, www.cgp.iiarjournals.org

Publication Data: CANCER GENOMICS & PROTEOMICS (CGP) is published bimonthly online-only and open access through High Wire Press, Stanford, USA. Each annual volume contains six issues. Annual Authors and Subject Indexes are included in the sixth issue of each volume.

Copyright: Once a manuscript has been published in CGP, which is a copyrighted publication, the legal ownership of all published parts of the paper passes from the Author to the Journal.

Manuscripts, correspondence and reprint orders should be addressed to: Dr. George J. Delinasios, Managing Editor, Editorial Office, Cancer Genomics & Proteomics, 1st km Kapandritiou-Kalamou Road, P.O. Box 22, Kapandriti, Attiki, 19014, Greece. Tel: +30 22950 52945, Fax: +30 2295053389, e-mail: journals@iiar-anticancer.org (Editorial Office); editor@iiar-anticancer.org (Managing Editor).

U.S. Branch: Anticancer Research USA, Inc., 111 Bay Avenue, Highlands, NJ 07732, USA.

Manuscripts from North America may be sent to the Editor-in-Chief, Prof. A. Seth, CGP, Laboratory of Molecular Pathology, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, ON, Canada M4N 3M5. Fax: 416 978 5956, e-mail: genomics.proteomics@utoronto.ca

The Editors and Publishers of the journal CANCER GENOMICS & PROTEOMICS accept no responsibility for the opinions expressed by the contributors or for the content of the advertisements appearing therein.